<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties manuscript?><front><journal-meta><journal-id journal-id-type="nlm-journal-id">2985236R</journal-id><journal-id journal-id-type="pubmed-jr-id">5595</journal-id><journal-id journal-id-type="nlm-ta">Med Clin North Am</journal-id><journal-id journal-id-type="iso-abbrev">Med. Clin. North Am.</journal-id><journal-title-group><journal-title>The Medical clinics of North America</journal-title></journal-title-group><issn pub-type="ppub">0025-7125</issn><issn pub-type="epub">1557-9859</issn></journal-meta><article-meta><article-id pub-id-type="pmid">22443982</article-id><article-id pub-id-type="pmc">6106779</article-id><article-id pub-id-type="doi">10.1016/j.mcna.2012.01.015</article-id><article-id pub-id-type="manuscript">HHSPA982889</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Thyroid Emergencies</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Klubo-Gwiezdzinska</surname><given-names>Joanna</given-names></name><degrees>MD, PhD</degrees><xref ref-type="aff" rid="A1">a</xref><xref ref-type="aff" rid="A2">b</xref></contrib><contrib contrib-type="author"><name><surname>Wartofsky</surname><given-names>Leonard</given-names></name><degrees>MD, MPH, MACP</degrees><xref ref-type="aff" rid="A3">c</xref><xref rid="CR1" ref-type="corresp">*</xref></contrib></contrib-group><aff id="A1"><label>a</label>Division of Endocrinology, Department of Medicine,
Washington Hospital Center, 110 Irving Street Northwest, Washington, DC 20010-2910,
USA</aff><aff id="A2"><label>b</label>Department of Endocrinology and Diabetology, Collegium
Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, ul. M.
Sklodowskiej-Curie 9, 85-094 Bydgoszcz, Poland</aff><aff id="A3"><label>c</label>Department of Medicine, Washington Hospital Center, 110
Irving Street Northwest, Washington, DC 20010-2910, USA</aff><author-notes><corresp id="CR1"><label>*</label>Corresponding author
<email>leonard.wartofsky@medstar.net</email></corresp></author-notes><pub-date pub-type="nihms-submitted"><day>29</day><month>7</month><year>2018</year></pub-date><pub-date pub-type="epub"><day>17</day><month>2</month><year>2012</year></pub-date><pub-date pub-type="ppub"><month>3</month><year>2012</year></pub-date><pub-date pub-type="pmc-release"><day>23</day><month>8</month><year>2018</year></pub-date><volume>96</volume><issue>2</issue><fpage>385</fpage><lpage>403</lpage><!--elocation-id from pubmed: 10.1016/j.mcna.2012.01.015--><abstract id="ABS1"><p id="P1">Thyroid emergencies are rare, life-threatening conditions resulting from
either severe deficiency of thyroid hormones (myxedema coma) or, by contrast,
decompensated thyrotoxicosis with the increased action of thyroxine (T4) and
triiodothyronine (T3) exceeding metabolic demands of the organism (thyrotoxic
storm). The understanding of the pathogenesis of these conditions, appropriate
recognition of the clinical signs and symptoms, and their prompt and accurate
diagnosis and treatment are crucial in optimizing survival.</p></abstract><kwd-group><kwd>Myxedema coma</kwd><kwd>Thyrotoxic storm</kwd><kwd>Diagnosis</kwd><kwd>Management</kwd></kwd-group></article-meta></front><body><sec id="S1"><title>MYXEDEMA COMA</title><sec id="S2"><title>Epidemiology and Precipitating Events</title><p id="P2">Myxedema coma is the extreme expression of severe hypothyroidism and
fortunately is rare, with an incidence rate of 0.22 per million per
year.<sup><xref rid="R1" ref-type="bibr">1</xref></sup> The most common
presentation of the syndrome is in hospitalized elderly women with long-standing
hypothyroidism, with 80% of cases occurring in women older than 60 years.
However, myxedema coma occurs in younger patients as well, with 36 documented
cases of pregnant women.<sup><xref rid="R2" ref-type="bibr">2</xref>,<xref rid="R3" ref-type="bibr">3</xref></sup></p><p id="P3">The syndrome will typically present in patients who develop a systemic
illness such as pulmonary or urinary infections, congestive heart failure, or
cerebrovascular accident (<xref rid="T1" ref-type="table">Table 1</xref>),
superimposed on previously undiagnosed hypothyroidism. Sometimes a history of
antecedent thyroid disease, thyroidectomy, treatment with radioactive iodine, or
T4 replacement therapy discontinued for no apparent reason can be elicited. A
pituitary or hypothalamic basis for hypothyroidism is encountered in about 5%
or, according to some studies, in up to 10% to 15% of patients.<sup><xref rid="R4" ref-type="bibr">4</xref></sup></p><p id="P4">Patients with myxedema coma generally present in the winter months,
suggesting that external cold may be an aggravating factor.<sup><xref rid="R5" ref-type="bibr">5</xref></sup> Some abnormalities such as hypoglycemia,
hypercalcemia, hyponatremia, hypercapnia, and hypoxemia, may be either
precipitating factors or secondary consequences of myxedema coma. Moreover, the
comatose state is associated with the risk of aspiration pneumonia and sepsis.
In hospitalized patients, drugs such as anesthetics, narcotics, sedatives,
antidepressants, and tranquilizers may depress respiratory drive and thereby
either cause or compound the deterioration of the hypothyroid patient into
coma.<sup><xref rid="R6" ref-type="bibr">6</xref>,<xref rid="R7" ref-type="bibr">7</xref></sup> The effect of these drugs should be taken
into consideration as a potential causative mechanism. In fact, Church and
Callen<sup><xref rid="R8" ref-type="bibr">8</xref></sup> described a
41-year-old male patient without any history of thyroid disease who developed
myxedema coma after being administered combined therapy with aripiprazole and
sertraline.</p><p id="P5">There is also a report of myxedema coma induced by chronic ingestion of
large amounts of raw bok choy. This Chinese white cabbage contains
glucosinolates, which break down products such as thiocyanates, nitriles, and
oxazolidines, and inhibit iodine uptake and production of thyroid hormones by
the thyroid gland. When eaten raw, digestion of the vegetable releases the
enzyme myrosinase, which accelerates production of the aforementioned thyroid
disruptors.<sup><xref rid="R9" ref-type="bibr">9</xref></sup></p></sec><sec id="S3"><title>Clinical Signs and Symptoms</title><p id="P6">Hypothermia (often profound to 80&#x000b0;F [26.7&#x000b0;C]) and
unconsciousness constitute 2 of the cardinal features of myxedema
coma.<sup><xref rid="R10" ref-type="bibr">10</xref></sup> Of importance
is that coincident infection may be masked by hypothyroidism, with a patient
presenting as afebrile despite an underlying severe infection. In view of the
latter and the fact that undiagnosed infection might lead inexorably to vascular
collapse and death, some authorities have advocated the routine use of
antibiotics in patients with myxedema coma. Underlying hypoglycemia may further
compound the decrement in body temperature.</p><p id="P7">Although coma is the predominant clinical presentation, a history of
disorientation, depression, paranoia, or hallucinations (myxedema madness) may
often be elicited. The neurologic findings may also include cerebellar signs
(poorly coordinated purposeful movements of the hands and feet, ataxia,
adiadochokinesia), poor memory and recall, or even frank amnesia, and abnormal
findings on electroencephalography (low amplitude and a decreased rate of
&#x003b1;-wave activity). Status epilepticus has been also described<sup><xref rid="R11" ref-type="bibr">11</xref></sup> and up to 25% of patients may
experience seizures possibly related to hyponatremia, hypoglycemia, or
hypoxemia.</p></sec><sec id="S4"><title>Respiratory System</title><p id="P8">The mechanism for hypoventilation in profound myxedema is a combination
of a depressed hypoxic respiratory drive and a depressed ventilatory response to
hypercapnia.<sup><xref rid="R12" ref-type="bibr">12</xref>,<xref rid="R13" ref-type="bibr">13</xref></sup> Partial obstruction of the
upper airway caused by edema of the tongue or vocal cords may also play a role.
Hypothyroid patients may be predisposed to increased airway hyperresponsiveness
and chronic inflammation.<sup><xref rid="R14" ref-type="bibr">14</xref></sup>
Tidal volume may be additionally reduced by other factors such as pleural
effusion or ascites. to achieve appropriately effective pulmonary function in
myxedema coma, prolonged mechanically assisted ventilation is usually
required.</p></sec><sec id="S5"><title>Cardiovascular Manifestations</title><p id="P9">Patients diagnosed with myxedema coma are at increased risk for shock and
potentially fatal arrhythmias. Typical electrocardiographic (ECG) findings
include bradycardia, varying degrees of block, low voltage, flattened or
inverted T waves, and prolonged Q-T interval, which can result in torsades de
pointes ventricular tachycardia.<sup><xref rid="R15" ref-type="bibr">15</xref></sup> Myocardial infarction should also be ruled out by the usual
diagnostic procedures, because aggressive or injudicious T4 replacement may
increase the risk of myocardial infarction. Moreover, cardiac contractility is
impaired, leading to reduced stroke volume and cardiac output. Reduced stroke
volume in severe cases may also be due to the cardiac tamponade caused by the
accumulation of fluid rich in mucopolysaccharides within the pericardial
sac.</p></sec><sec id="S6"><title>Electrolyte Disturbances and Renal Manifestations</title><p id="P10">Hyponatremia is a common finding observed in patients with myxedema
coma. The mechanism accounting for the hyponatremia is associated with increased
serum anti-diuretic hormone<sup><xref rid="R16" ref-type="bibr">16</xref></sup>
and impaired water diuresis caused by reduced delivery of water to the distal
nephron.<sup><xref rid="R17" ref-type="bibr">17</xref></sup> Depending
on its duration and severity, hyponatremia will add to altered mental status,
and when severe may be largely responsible for precipitating the comatose state.
Alterations in renal function observed in myxedema coma include decreases in
glomerular filtration rate and renal plasma flow, and increases in total body
water. Atony of the urinary bladder with retention of large residual urine
volumes is commonly seen. Renal failure may occur as a result of underlying
rhabdomyolysis with extremely high levels of creatine kinase.<sup><xref rid="R18" ref-type="bibr">18</xref>&#x02013;<xref rid="R21" ref-type="bibr">21</xref></sup></p></sec><sec id="S7"><title>Gastrointestinal Manifestations</title><p id="P11">The gastrointestinal tract in myxedema may be marked by
mucopolysaccharide infiltration and edema of the muscularis, as well as
neuropathic changes leading to gastric atony, impaired peristalsis, and even
paralytic ileus. Ascites may occur, and has been documented in one report of 51
cases.<sup><xref rid="R22" ref-type="bibr">22</xref></sup> Another
potential complication is gastrointestinal bleeding secondary to an associated
coagulopathy.<sup><xref rid="R23" ref-type="bibr">23</xref></sup> It is
important to recognize the underlying mechanisms of these acute gastrointestinal
complications so as to avoid unnecessary surgery for an apparent acute
abdomen.<sup><xref rid="R24" ref-type="bibr">24</xref></sup></p></sec><sec id="S8"><title>Hematological Manifestations</title><p id="P12">In contrast to the tendency to thrombosis seen in mild hypothyroidism,
severe hypothyroidism is associated with a higher risk of bleeding caused by
coagulopathy related to an acquired von Willebrand syndrome (type 1) and
decreases in factors V, VII, VIII, IX, and X.<sup><xref rid="R25" ref-type="bibr">25</xref></sup> The von Willebrand syndrome is
reversible with T4 therapy.<sup><xref rid="R26" ref-type="bibr">26</xref></sup>
Another cause of bleeding may be disseminated intravascular coagulation
associated with sepsis. Patients with myxedema coma have increased preponderance
to severe infections, including sepsis, because of granulocytopenia and a
decreased cell-mediated immunologic response. Such patients may also present
with a microcytic anemia secondary to hemorrhage, or a macrocytic anemia caused
by vitamin B<sub>12</sub> deficiency, which may also worsen the neurologic
state.</p></sec><sec id="S9"><title>Diagnosis</title><p id="P13">To summarize the aforementioned clinical manifestations, the typical
patient presenting with myxedema coma is a woman in the later decades of life
who may have a history of thyroid disease and who is admitted to hospital,
typically in winter, with pneumonia. Physical findings could include
bradycardia, macroglossia, hoarseness, delayed reflexes, dry skin, general
cachexia, hypoventilation, and hypothermia, commonly without shivering.
Laboratory evaluation may indicate hypoxemia, hypercapnia, anemia, hyponatremia,
hypercholesterolemia, and increased serum lactate dehydrogenase and creatine
kinase. On lumbar puncture there is increased pressure and the cerebrospinal
fluid has high protein content.</p><p id="P14">Although an elevated serum thyrotropin (TSH) concentration is the most
important laboratory evidence for the diagnosis, the presence of severe
complicating systemic illness or treatment with drugs such as dopamine,
dobutamine, or corticosteroids may serve to reduce the elevation in TSH
levels.<sup><xref rid="R27" ref-type="bibr">27</xref>,<xref rid="R28" ref-type="bibr">28</xref></sup> There may also be a pituitary cause for
the hypothyroidism, in which case an increased TSH would not be found.</p></sec><sec id="S10"><title>Treatment</title><p id="P15">Myxedema coma as a true medical emergency requires a multifaceted
approach to treatment in a critical care setting.</p><sec id="S11"><title>Airways and ventilation</title><p id="P16">The patient&#x02019;s comatose state is perpetuated by
hypoventilation, with CO<sub>2</sub> retention and respiratory acidosis. The
maintenance of an adequate airway is the single most important supportive
measure, because of the high mortality rate associated with the inexorable
respiratory failure. Mechanical ventilation is usually required during the
first 36 to 48 hours, but in some patients it may be necessary to continue
assisted ventilation for as long as 2 to 3 weeks. The hypercapnia may be
rapidly relieved with mechanical ventilation, but the hypoxia tends to
persist, possibly because of shunting in nonaerated lung areas.<sup><xref rid="R29" ref-type="bibr">29</xref></sup> It is advisable,
therefore, not to extubate the patients prematurely and to wait until full
consciousness is attained.</p></sec><sec id="S12"><title>Thyroid hormone therapy</title><p id="P17">One of the most controversial aspects of the management of myxedema
coma is which thyroid hormone preparation to give and how to give it (dose,
frequency, and route of administration). The optimum treatment remains
uncertain, because of the scarcity of clinical studies and obvious
difficulties with performing controlled trials. There is a necessity to
balance the need for quickly attaining physiologically effective thyroid
hormone levels against the risk of precipitating a fatal tachyarrhythmia or
myocardial infarction. All patients should have continuous ECG monitoring,
with reduction in thyroid hormone dosage should arrhythmias or ischemic
changes be detected.</p><p id="P18">Parenteral preparations of either T4 or T3 are available for
intravenous administration. Although oral forms of either T3 or T4 can be
given by nasogastric tube in the comatose patient, this route is fraught
with risks of aspiration and uncertain absorption, particularly in the
presence of gastric atony or ileus. The single intravenous bolus of T4 was
popularized by reports<sup><xref rid="R30" ref-type="bibr">30</xref></sup>
suggesting that replacement of the entire estimated pool of extrathyroidal
T4 (usually 300&#x02013;600 &#x003bc;g) was desirable to restore near-normal
hormonal status. This initial loading dose is followed by the maintenance
dose of 50 to 100 &#x003bc;g given daily (either intravenously or by mouth if
the patient is adequately alert). Larger doses of T4 probably have no
advantage and may, in fact, be more dangerous.<sup><xref rid="R31" ref-type="bibr">31</xref></sup> There is also evidence showing
improved outcomes with lower doses of thyroid hormone.<sup><xref rid="R32" ref-type="bibr">32</xref></sup> Rodriguez and colleagues<sup><xref rid="R1" ref-type="bibr">1</xref></sup> performed a prospective
trial in which patients were randomized to receive either a 500-&#x003bc;g
loading dose of T4 followed by a 100-&#x003bc;g daily maintenance dose, or
only the maintenance dose. The overall mortality rate was 36.4%, with a
lower mortality rate in the high-dose group (17%) than in the low-dose group
(60%). Although suggestive, the difference was not statistically
significant.</p><p id="P19">The rate of conversion of T4 to T3 is reduced in many systemic
illnesses (the euthyroid sick or low T3 syndrome),<sup><xref rid="R28" ref-type="bibr">28</xref></sup> hence T3 generation may be reduced
in myxedema coma as a consequence of any associated illness (hypothyroid
sick syndrome). As a consequence, some clinicians suggest that small
supplements of T3 should be given along with T4 during the initial few days
of treatment, especially if obvious associated illness is present. When
therapy is approached with T3 alone, it may be given as a 10-to 20-&#x003bc;g
bolus followed by 10 &#x003bc;g every 4 hours for the first 24 hours,
dropping to 10 &#x003bc;g every 6 hours for days 2 to 3, by which time oral
administration should be feasible.<sup><xref rid="R6" ref-type="bibr">6</xref></sup> T3 has a much quicker onset of action than T4, and
increases in body temperature and oxygen consumption may occur 2 to 3 hours
after intravenous T3, compared with 8 to 14 hours after intravenous T4. The
other advantage of T3 is that it crosses the blood-brain barrier more
rapidly than T4, which may be particularly important in patients with
profound neuropsychological symptoms.<sup><xref rid="R33" ref-type="bibr">33</xref></sup> One clinical example of the possible benefit of T3
is a case report of a patient with myxedema coma and cardiogenic shock who
responded to T3 therapy but not to T4 therapy.<sup><xref rid="R34" ref-type="bibr">34</xref></sup> On the other hand, treatment with T3
alone is associated with large and unpredictable fluctuations in serum T3
levels, and high serum T3 levels during treatment have been associated with
fatal outcomes.<sup><xref rid="R35" ref-type="bibr">35</xref></sup> A more
conservative but seemingly rational approach is to provide combined therapy
with both T4 and T3.<sup><xref rid="R36" ref-type="bibr">36</xref></sup>
Rather than administer 300 to 500 &#x003bc;g T4 intravenously initially, a
dose of 4 &#x003bc;g/kg lean body weight (or about 200&#x02013;300 &#x003bc;g)
is given, and an additional 100 &#x003bc;g is given 24 hours later. By the
third day, the dose is reduced to a daily maintenance dose of 50 &#x003bc;g,
which can be given by mouth as soon as the patient is conscious.<sup><xref rid="R36" ref-type="bibr">36</xref></sup> Simultaneously with the
initial dose of T4, a bolus of 10 &#x003bc;g T3 is given and intravenous T3
is continued at a dosage of 10 &#x003bc;g every 8 to 12 hours until the
patient is conscious and taking maintenance T4. Clinical improvement has
been seen with even a single dose of only 2.5 &#x003bc;g of T3.<sup><xref rid="R37" ref-type="bibr">37</xref></sup></p></sec><sec id="S13"><title>Hypothermia</title><p id="P20">Treatment with T4 and/or T3 enables restoration of body temperature
to normal. Simultaneously, blankets or increasing the room temperature can
be used as additional interventions to keep the patient warm until the
thyroid hormone effect is achieved. Too aggressive warming may cause
peripheral vasodilatation, which may then lead to hypotension or shock.</p></sec><sec id="S14"><title>Hypotension</title><p id="P21">Hypotension should also be correctable by treatment with T4 and/or
T3. However, a hypotensive patient may require additional volume-repletion
therapy. Fluids may be administered cautiously as 5% to 10% glucose in 0.5 N
sodium chloride if hypoglycemia is present, or as isotonic normal saline if
hyponatremia is present. An agent such as dopamine might be used to maintain
coronary blood flow, but patients should be weaned off the vasopressor as
soon as possible because of the risk of a pressor-induced ischemic
event.</p><p id="P22">Because of the risk of relative adrenal insufficiency, it is wise to
administer hydrocortisone until the hypotension is corrected. The typical
dosage of hydrocortisone is 50 to 100 mg every 6 to 8 hours during the first
7 to 10 days, with tapering of the dosage thereafter based on clinical
response and any plans for further diagnostic evaluation. Decreased adrenal
reserve has been found in 5% to 10% of patients, based on either
hypopituitarism or primary adrenal failure accompanying Hashimoto disease
(Schmidt syndrome). The other rationale for the treatment with
corticosteroids is the potential risk of precipitating acute adrenal
insufficiency caused by the accelerated metabolism of cortisol that follows
T4 therapy. The clinicians should be aware of signs and symptoms signaling
coexisting adrenal insufficiency such as hypotension, hypothermia,
hypoglycemia, hyperkalemia, and hyponatremia.</p></sec><sec id="S15"><title>Hyponatremia</title><p id="P23">Low serum sodium may cause a semicomatose state or seizures even in
euthyroid patients, and the severe hyponatremia (105&#x02013;120 mmol/L) in
profound myxedema is likely to contribute substantially to the coma in these
patients. Mortality rates in critically ill patients with symptomatic
hyponatremia have been reported to be 60-fold higher than in patients
without hyponatremia.<sup><xref rid="R38" ref-type="bibr">38</xref></sup>
The appropriate management of severe hyponatremia often requires
administration of a small amount of hypertonic saline (50&#x02013;100 mL 3%
sodium chloride), enough to increase sodium concentration by about 2 mmol/L
early in the course of treatment, followed by an intravenous bolus dose of
40 to 120 mg furosemide to promote a water diuresis.<sup><xref rid="R39" ref-type="bibr">39</xref></sup> A small, quick increase in the serum
sodium concentration (2&#x02013;4 mmol/L) is effective in acute hyponatremia
because even a slight reduction in brain swelling results in a substantial
decrease in intracerebral pressure.<sup><xref rid="R40" ref-type="bibr">40</xref></sup> On the other hand, too rapid correction of
hyponatremia can cause a dangerous complication, the osmotic demyelinization
syndrome. In patients with chronic hyponatremia, this complication is
avoided by limiting the sodium correction to less than 10 to 12 mmol/L in 24
hours and less than 18 mmol/L in 48 h. After achieving a sodium level of
more than 120 mmol/L, restriction of fluids may be all that is necessary to
correct hyponatremia. It must be emphasized that fluid or saline therapy
requires careful monitoring of volume status based on clinical parameters
and measurements of central venous pressure, especially in patients with
significant cardiovascular decompensation.</p><p id="P24">The other therapeutic option is treatment with an intravenous
vasopressin antagonist, conivaptan. Conivaptan has been approved by the US
Food and Drug Administration for the treatment of hospitalized patients with
euvolemic and hypervolemic hyponatremia in a setting of the syndrome of
inappropriate secretion of antidiuretic hormone, hypothyroidism, adrenal
insufficiency, or pulmonary disorders.<sup><xref rid="R41" ref-type="bibr">41</xref></sup> The rationale for application of conivaptan in this
clinical setting is based on the high vasopressin levels observed in
myxedema coma. Current dosing recommendations are for a 20-mg loading dose
to be infused over 30 minutes followed by 20 mg/d continuous infusion for up
to 4 days. Unfortunately, no data are available on the use of conivaptan in
severe hyponatremia (&#x0003c;115 mEq/L) in hypothyroid patients.<sup><xref rid="R42" ref-type="bibr">42</xref>,<xref rid="R43" ref-type="bibr">43</xref></sup></p></sec><sec id="S16"><title>General supportive measures</title><p id="P25">In addition to the specific therapies outlined, other treatments
will be indicated as in the management of any other elderly patient with
multisystem problems. Management might include the treatment of underlying
problems such as infection, congestive heart failure, diabetes, or
hypertension. The dosage of specific medications (eg, digoxin for congestive
heart failure) may need to be modified based on their altered distribution
and slowed metabolism in myxedema.</p></sec></sec><sec id="S17"><title>Prognosis</title><p id="P26">Even with this vigorous therapy, the prognosis for myxedema coma remains
grim, and patients with severe hypothermia and hypotension seem to do the worst.
In the past the mortality rate was as high as 60% to 70%, but this has now been
reduced to 20%&#x02013;25% with the advances in intensive care
management.<sup><xref rid="R44" ref-type="bibr">44</xref></sup> Several
prognostic factors may be associated with a fatal outcome,<sup><xref rid="R1" ref-type="bibr">1</xref>,<xref rid="R5" ref-type="bibr">5</xref>,<xref rid="R32" ref-type="bibr">32</xref>,<xref rid="R35" ref-type="bibr">35</xref>,<xref rid="R45" ref-type="bibr">45</xref></sup> and include
older age, persistent hypothermia or bradycardia, lower degree of consciousness
by Glasgow Coma Scale, multiorgan impairment indicated by an APACHE II score
(Acute Physiology and Chronic Health Evaluation) of more than 20, or SOFA score
(Sequential Organ Failure Assessment) of more than 6. The most common causes of
death are respiratory failure, sepsis, and gastrointestinal bleeding. Early
diagnosis and prompt treatment, with meticulous attention to the details of
management during the first 48 hours, remain critical for effective therapy.</p></sec></sec><sec id="S18"><title>THYROTOXIC STORM</title><p id="P27">Thyroid crisis or thyrotoxic storm is characterized by severely exaggerated
manifestations of thyrotoxicosis. The underlying cause of thyrotoxicosis is commonly
Graves disease or toxic multinodular goiter. Rarely, thyrotoxic storm may occur with
subacute thyroiditis or factitious thyrotoxicosis caused by intentional thyroxine
overdose.<sup><xref rid="R46" ref-type="bibr">46</xref>,<xref rid="R47" ref-type="bibr">47</xref></sup></p><sec id="S19"><title>Epidemiology and Precipitating Events</title><p id="P28">An accurate estimation of the incidence of thyroid storm is impossible
to determine because of the considerable variability in the criteria for its
diagnosis. The syndrome does appear to be less common today than in the past,
perhaps because of earlier diagnosis and treatment of thyrotoxicosis, thereby
precluding its progression to the stage of crisis. Nevertheless, it may occur in
1% to 2% of hospital admissions for thyrotoxicosis.<sup><xref rid="R48" ref-type="bibr">48</xref></sup> Thyrotoxic storm is rarely seen after
thyroid surgery, because of the routine preparation of patients for elective
thyroidectomy by treatment with antithyroid drugs. However, several types of
nonthyroidal surgeries or other traumas have precipitated surgical thyrotoxic
storm in patients with previously undiagnosed thyrotoxicosis. The crisis may be
related to perioperative events, such as anesthesia, stress, and volume
depletion, because these conditions are associated with increases in the
concentration of free thyroid hormone. Thyroid storm has been seen in pregnancy,
during labor, and in complicated deliveries such as those with placenta
previa.<sup><xref rid="R49" ref-type="bibr">49</xref></sup> An acute
discharge of hormones in the appropriate clinical setting may trigger a crisis,
and cases have been reported following vigorous palpation of the thyroid,
radioactive iodine therapy,<sup><xref rid="R50" ref-type="bibr">50</xref></sup>
withdrawal of propylthiouracil therapy, or after administration of lithium,
stable iodine, or iodinated contrast dyes. The other conditions known to be
associated with increased free fraction of T4 and T3 include stress, infections,
burns, cytotoxic chemotherapy for acute leukemia, aspirin overdose,
ketoacidosis, or organophosphate intoxication (see <xref rid="T1" ref-type="table">Table 1</xref>).<sup><xref rid="R45" ref-type="bibr">45</xref>,<xref rid="R51" ref-type="bibr">51</xref>&#x02013;<xref rid="R55" ref-type="bibr">55</xref></sup> Amiodarone, an antiarrhythmic
and antianginal drug that is also rich in iodine, may cause either an
iodine-induced thyrotoxicosis (type 1) or a destructive thyroiditis (type 2);
the latter has been reported as a cause of thyroid storm refractory to the usual
treatment.<sup><xref rid="R56" ref-type="bibr">56</xref></sup> There is
also a case report of thyrotoxic storm precipitated by food poisoning with
marine neurotoxin after ingestion of seafood.<sup><xref rid="R57" ref-type="bibr">57</xref></sup> Notwithstanding the multiplicity of
precipitating factors, in hospitalized patients the most common event associated
with thyrotoxic storm is some type of infection.</p></sec><sec id="S20"><title>Clinical Signs and Symptoms</title><p id="P29">The clinical diagnosis is based on the identification of signs and
symptoms that suggest decompensation of several organ systems. Some of these
cardinal manifestations include fever out of proportion to an apparent infection
and dramatic diaphoresis. Hyperthermia in thyroid crisis can represent defective
thermoregulation by the hypothalamus and/or increased basal metabolic rate,
increased oxidation of lipids being responsible for more than 60% of the resting
energy expenditure.<sup><xref rid="R58" ref-type="bibr">58</xref></sup> The
other key components of thyrotoxic storm include tachycardia out of proportion
to the fever, and gastrointestinal dysfunction, which can include nausea,
vomiting, diarrhea and, in severe cases, jaundice. As the storm progresses,
symptoms of central nervous system dysfunction simulating an encephalopathic
picture will appear, which may include increasing agitation and emotional
lability, confusion, paranoia, psychosis, and coma.<sup><xref rid="R59" ref-type="bibr">59</xref></sup> Patients have been reported who
presented with thyroid storm associated with status epilepticus and stroke and
with bilateral basal ganglia infarction.<sup><xref rid="R60" ref-type="bibr">60</xref></sup> In patients with neurologic symptoms, a high index of
suspicion for cerebral sinus thrombosis should be considered, because of the
higher prevalence of this condition in severe hyperthyroidism.<sup><xref rid="R61" ref-type="bibr">61</xref></sup> Paralysis observed in thyroid
crisis might be due to not only the cerebrovascular accident but also thyrotoxic
periodic paralysis with hypokalemia, as frequently may present in Asian
men.<sup><xref rid="R62" ref-type="bibr">62</xref></sup> In older
patients, the thyrotoxic storm may present as so-called masked or apathetic
thyrotoxicosis.<sup><xref rid="R63" ref-type="bibr">63</xref></sup></p></sec><sec id="S21"><title>Cardiovascular Manifestations</title><p id="P30">The most common cardiovascular manifestations are rhythm disturbances
such as sinus tachycardia, atrial fibrillation, or other supraventricular
tachyarrhythmias, and rarely, ventricular tachyarrhythmias, which can be
observed even in patients without previous heart disease.<sup><xref rid="R64" ref-type="bibr">64</xref></sup> Congestive heart failure or a reversible
dilated cardiomyopathy<sup><xref rid="R65" ref-type="bibr">65</xref></sup> also
may be present even in young or middle-aged patients without known antecedent
cardiac disease. A high-output state is present, attributable to the increased
preload secondary to activation of the renin-angiotensin-aldosterone axis and to
decreased afterload secondary to a direct relaxing effect of thyroid hormones on
vascular muscle cells. Therefore, most patients present with systolic
hypertension with widened pulse pressure. The hyperthyroid heart is
characterized by higher than usual oxygen demands and hence myocardial
infarction can be observed, even in young patients.<sup><xref rid="R66" ref-type="bibr">66</xref>,<xref rid="R67" ref-type="bibr">67</xref></sup> A relatively rare complication of severe hyperthyroidism is
pulmonary hypertension, which is presumed to be on an autoimmune basis when
associated with Graves disease, but which also may be secondary to an augmented
blood volume, cardiac output, and sympathetic tone, leading to pulmonary
vasoconstriction and increased pulmonary arterial pressure. This condition is
usually reversible after treatment with antithyroid drugs. The other possible
reason for pulmonary hypertension is pulmonary embolism caused by the thrombotic
or hypercoagulable state that has been observed in severe hyperthyroidism.</p></sec><sec id="S22"><title>Respiratory Manifestations</title><p id="P31">The main pulmonary symptom is dyspnea and tachypnea related to an
increased oxygen demand. The excessive work of the respiratory muscles may
eventually lead to diaphragmatic dysfunction.<sup><xref rid="R68" ref-type="bibr">68</xref></sup> Respiratory failure may result from the
hyperdynamic cardiomyopathy but also from preexistent underlying pulmonary
disease.<sup><xref rid="R69" ref-type="bibr">69</xref>,<xref rid="R70" ref-type="bibr">70</xref></sup></p></sec><sec id="S23"><title>Gastrointestinal Manifestations</title><p id="P32">The most common symptoms are diarrhea and vomiting, which can aggravate
volume depletion, postural hypotension, and shock with vascular collapse. The
diffuse abdominal pain, possibly caused by impaired neurohormonal regulation of
gastric myoelectrical activity with delayed gastric emptying,<sup><xref rid="R71" ref-type="bibr">71</xref></sup> may even lead to a
presentation such as acute abdomen<sup><xref rid="R72" ref-type="bibr">72</xref></sup> or intestinal obstruction.<sup><xref rid="R73" ref-type="bibr">73</xref></sup> The liver function abnormalities and
presence of jaundice warrant immediate and vigorous therapy. Although most
presentations of an acute abdomen in thyrotoxicosis are medical in nature,
surgical conditions may also occur.<sup><xref rid="R74" ref-type="bibr">74</xref></sup></p></sec><sec id="S24"><title>Electrolyte Disturbances and Renal Manifestations</title><p id="P33">Increased serum calcium levels, caused by both hemoconcentration and
known effects of thyroid hormone on bone resorption, may be seen. The sodium,
potassium, and chloride levels are usually normal. Because of the augmented
lipolysis and ketogenesis, and the basal metabolic demands that exceed oxygen
delivery, ketoacidosis and lactic acidosis are observed.</p><p id="P34">Hyperthyroidism is often associated with an accelerated glomerular
filtration rate, which may progress to glomerulosclerosis and excessive
proteinuria. There are case reports of renal failure caused by
rhabdomyolysis,<sup><xref rid="R75" ref-type="bibr">75</xref></sup>
urinary retention associated with dyssynergy of the detrusor muscle and bladder
dysfunction,<sup><xref rid="R76" ref-type="bibr">76</xref></sup> and an
autoimmune complex&#x02013;mediated nephritis concomitant with Graves
disease.<sup><xref rid="R77" ref-type="bibr">77</xref></sup></p></sec><sec id="S25"><title>Hematological Manifestations</title><p id="P35">A moderate leukocytosis with a mild shift to the left is a common
finding, even in the absence of infection. Hyperthyroidism may be associated
with hypercoagulability caused by increased concentrations of fibrinogen,
factors VIII and IX, tissue plasminogen activator inhibitor 1, von Willebrand
factor, increase in red blood cell mass secondary to erythropoietin
upregulation, and a tendency to augmented platelet plug formation.<sup><xref rid="R78" ref-type="bibr">78</xref></sup> Major thromboembolic
complications are responsible for 18% of deaths caused by
thyrotoxicosis.<sup><xref rid="R79" ref-type="bibr">79</xref>&#x02013;<xref rid="R83" ref-type="bibr">83</xref></sup></p></sec><sec id="S26"><title>Diagnosis</title><p id="P36">Diagnosis can be established predominantly on the basis of clinical
presentation, because the laboratory findings may not be much different than
those observed in uncomplicated hyperthyroidism. Indeed, serum total T3 levels
may be even within normal limits, as these patients may have some underlying
precipitating illness that reduces T4 to T3 conversion as is seen in the
euthyroid sick syndrome.<sup><xref rid="R84" ref-type="bibr">84</xref></sup>
Therefore, a semiquantitative scale (<xref rid="T2" ref-type="table">Table
2</xref>) assessing the presence and severity of the most common signs and
symptoms has been developed to aid in the diagnosis.<sup><xref rid="R85" ref-type="bibr">85</xref></sup></p><p id="P37">Other laboratory abnormalities may include a modest hyperglycemia in the
absence of diabetes mellitus, probably as a result of augmented glycogenolysis
and catecholamine-mediated inhibition of insulin release, as well as increased
insulin clearance and insulin resistance. When thyrotoxicosis is prolonged,
leading to the depletion of glycogen deposits, hypoglycemia may occur,
particularly in older people when aggravated by malnutrition secondary to emesis
or abdominal pain.<sup><xref rid="R86" ref-type="bibr">86</xref></sup> Hepatic
dysfunction in thyroid storm results in elevated levels of serum lactate
dehydrogenase, aspartate aminotransferase, and bilirubin. Increased levels of
serum alkaline phosphatase are also observed, predominantly because of increased
osteoblastic bone activity in response to the augmentation of bone
resorption.</p><p id="P38">Of importance, adrenal reserve may be exceeded in thyrotoxic crisis
because of the inability of the adrenal gland to meet the metabolic demands and
accelerated turnover of glucocorticoids. Moreover, there is known coincidence of
adrenal insufficiency with Graves disease. This diagnosis should be considered
when there is hypotension and suggestive electrolyte abnormalities.</p></sec><sec id="S27"><title>Treatment</title><p id="P39">To avoid a disastrous outcome, a complex approach to management is
recommended.<sup><xref rid="R87" ref-type="bibr">87</xref></sup> First,
specific antithyroid drugs must be used to reduce the increased thyroid
production and release of T4 and T3. The second approach comprises treatment
intended to block the effects of the remaining but excessive circulating
concentrations of free T4 and T3 in blood. The third arm involves treatment of
any systemic decompensation, for example, congestive heart failure, and shock.
The final component addresses any underlying precipitating illness such as
infection or ketoacidosis.</p><sec id="S28"><title>Therapy directed to the thyroid gland</title><p id="P40">Inhibition of new synthesis of the thyroid hormones is achieved by
administration of thionamide antithyroid drugs, such as carbimazole,
methimazole (Tapazole), and propylthiouracil. These drugs in the comatose or
uncooperative patient are given by nasogastric tube or per rectum as enemas
or suppositories.<sup><xref rid="R88" ref-type="bibr">88</xref>&#x02013;<xref rid="R91" ref-type="bibr">91</xref></sup> There are no available
intravenous preparations of these compounds in the United States, but they
are successfully used in some European countries such as the United Kingdom,
Germany, and Poland.<sup><xref rid="R92" ref-type="bibr">92</xref>&#x02013;<xref rid="R94" ref-type="bibr">94</xref></sup>
According to the recently published guidelines by the American Thyroid
Association and the Association of Clinical Endocrinologists,
propylthiouracil can be started with a loading dose of 500 to 1000 mg
followed by 250 mg every 4 hours, and methimazole should be administered at
daily dose of 60 to 80 mg.<sup><xref rid="R87" ref-type="bibr">87</xref></sup> It is thought that propylthiouracil will provide more
rapid clinical improvement because it has the additional advantage of
inhibiting conversion of T4 to T3, a property not shared by methimazole.
Because thionamides reduce new hormone synthesis but not thyroidal secretion
of preformed glandular stores of hormone, separate treatment must be
administered to inhibit proteolysis of colloid and the continuing release of
T4 and T3 into the blood. Either inorganic iodine or lithium carbonate may
be used for this purpose. Iodides may be given either orally as Lugol
solution or as a saturated solution of potassium iodide (3&#x02013;5 drops
every 6 hours). An earlier mainstay of treatment, the use of an intravenous
infusion of sodium iodide (0.5&#x02013;1 g every 12 hours), has not been
feasible recently because sterile sodium iodide has not been available for
intravenous use.</p><p id="P41">It is important that iodine should be administered no sooner than 1
hour after prior thionamide dosage. Otherwise iodine will enhance thyroid
hormone synthesis, enrich hormone stores within the gland, and thereby
permit further exaggeration of thyrotoxicosis. When iodine is administered
in conjunction with full doses of antithyroid drugs, dramatic rapid
decreases in serum T4 are seen, with values approaching the normal range
within 4 or 5 days.<sup><xref rid="R95" ref-type="bibr">95</xref></sup>
Other agents that theoretically could be used in this manner are the
radiographic contrast dyes ipodate (Oragrafin) and iopanoic acid
(Telepaque), which act not only by decreasing thyroid hormone release but
also by slowing the peripheral conversion of T4 to T3, as well as possibly
blocking binding of both T3 and T4 to their cellular receptors.
Unfortunately, these agents are no longer available in the United
States.</p><p id="P42">In patients who may be allergic to iodine, lithium carbonate may be
used as an alternative agent to inhibit hormonal release.<sup><xref rid="R96" ref-type="bibr">96</xref>,<xref rid="R97" ref-type="bibr">97</xref></sup> Lithium should be administered initially as 300 mg
every 6 hours, with subsequent adjustment of dosage as necessary to maintain
serum lithium levels at about 0.8 to 1.2 mEq/L.</p></sec><sec id="S29"><title>Therapy directed at the continuing effects of thyroid hormone in the
periphery</title><p id="P43">Given the presence and likelihood of high levels of circulating T4
and T3 in a large vascular pool and tissue distribution space, in severe
cases treatment with antithyroid drugs alone is not sufficient.
Plasmapheresis and therapeutic plasma exchange are effective alternative
therapies, which can reduce T4 and T3 levels within 36 hours. Plasma or
albumin solution given during therapeutic plasma exchange provides new
binding sites to reduce circulating levels of free thyroid
hormones.<sup><xref rid="R98" ref-type="bibr">98</xref>&#x02013;<xref rid="R100" ref-type="bibr">100</xref></sup> However, this effect is
transient and lasts only about 24 to 48 hours, and thus should be followed
by a more definitive therapy. Early thyroidectomy has been reported to
reduce the mortality rate from 20% to 40% under standard treatment to less
than 10%.<sup><xref rid="R101" ref-type="bibr">101</xref></sup></p><p id="P44">Peritoneal dialysis or experimental hemoperfusion through a resin
bed<sup><xref rid="R102" ref-type="bibr">102</xref></sup> or
charcoal columns<sup><xref rid="R103" ref-type="bibr">103</xref></sup> has
also been used. Another therapeutic adjunct is the oral administration of
cholestyramine resin, resulting in removal of T4 and T3 by binding thyroid
hormone entering the gut via enterohepatic recirculation, with the
subsequent excretion of the resin-hormone complex.<sup><xref rid="R104" ref-type="bibr">104</xref></sup></p><p id="P45">Hughes<sup><xref rid="R105" ref-type="bibr">105</xref></sup> was the
first to treat a patient with thyrotoxic storm with a &#x003b2;-adrenergic
blocker to ameliorate the manifestations of thyroid hormone excess.
Propranolol is the most commonly used agent in the United States. The oral
dosage of 60 to 80 mg every 4 hours or intravenous doses of 0.5 to 1 mg
followed by subsequent doses of 2 to 3 mg given intravenously over 10 to 15
min every several hours are recommended, alongside constant cardiac rhythm
monitoring.<sup><xref rid="R87" ref-type="bibr">87</xref>,<xref rid="R106" ref-type="bibr">106</xref>,<xref rid="R107" ref-type="bibr">107</xref></sup> There may be a theoretical benefit
derived from the inhibitory effect of propranolol on the conversion of T4 to
T3,<sup><xref rid="R108" ref-type="bibr">108</xref></sup> but a
significant effect is seen only with oral doses higher than 160 mg/d. Usage
of &#x003b2;-blockers not only corrects the heart rate and diminishes the
oxygen demand of the cardiac muscle, but also improves agitation,
convulsions, psychotic behavior, tremor, diarrhea, fever, and diaphoresis.
In some patients, there may be a relative risks or contraindications to the
use of these agents. In patients with a history of bronchospasm or asthma
and treatment with either selective &#x003b2;1-blockers or reserpine,
guanethidine should be considered instead. A short-acting
&#x003b2;-adrenergic blocker, esmolol, has also been used successfully in the
management of thyroid storm. An initial loading dose of 0.25 to 0.5 mg/kg is
followed by continuous infusion of 0.05 to 0.1 mg/kg per minute.<sup><xref rid="R109" ref-type="bibr">109</xref>,<xref rid="R110" ref-type="bibr">110</xref></sup></p><p id="P46">The other important medications characterized by a high therapeutic
potency and modest ability to inhibit peripheral conversion of T4 to T3 are
steroids. An initial dose of 300 mg hydrocortisone followed by 100 mg every
8 hours during the first 24 to 36 hours should be adequate. Thyroid storm
has been reported to recur when steroids had been discontinued after initial
clinical improvement.<sup><xref rid="R111" ref-type="bibr">111</xref></sup>
The additional rationale behind the routine use of steroids is perhaps
theoretical and unproven, but relates to possible relative adrenal
insufficiency secondary to increased metabolic demands and more rapid
turnover of cortisol.</p><p id="P47">Some authorities have suggested that the supplemental administration
of 1&#x003b1; (OH) vitamin D<sub>3</sub> might accelerate the reduction of
serum T4 and T3.<sup><xref rid="R112" ref-type="bibr">112</xref></sup> In a
recent study, the administration of 2 g/d L-carnitine in thyrotoxic storm
facilitated a dose reduction of methimazole. The mechanism appears to be
related to an inhibition by L-carnitine of T3 and T4 entry into cell
nuclei.<sup><xref rid="R113" ref-type="bibr">113</xref>,<xref rid="R114" ref-type="bibr">114</xref></sup> Although these
preliminary findings are of interest, the utility of this adjunct to therapy
requires confirmation.</p></sec><sec id="S30"><title>Therapy directed at systemic decompensation</title><p id="P48">Fluid depletion caused by hyperpyrexia and diaphoresis, as well as
by vomiting or diarrhea, must be vigorously replaced to avoid vascular
collapse. Appropriate fluid therapy will usually correct hypercalcemia, if
present. Judicious replacement of fluids is necessary in elderly patients
with congestive heart failure or other cardiac compromise. Intravenous
fluids containing 10% dextrose in addition to electrolytes will better
restore depleted hepatic glycogen. Vitamin supplements may be added to the
intravenous fluids to replace probable coexistent deficiency. Hypotension
not readily reversed by adequate hydration may temporarily require pressor
and/or glucocorticoid therapy.</p><p id="P49">For fever, acetaminophen rather than salicylates is the preferred
antipyretic, because salicylates inhibit thyroid hormone binding and could
increase free T4 and T3, thereby transiently worsening the thyrotoxic
crisis. Hyperthermia also responds well to external cooling with alcohol
sponging, cooling blankets, and ice packs. Some investigators advocate the
use of the skeletal muscle relaxant dantrolene,<sup><xref rid="R115" ref-type="bibr">115</xref></sup> but significant risk associated
with its use precludes routine recommendation. When present, congestive
heart failure should be treated routinely. Although less commonly used
today, when digoxin is used, larger than usual doses may be required because
of its increased turnover in the thyrotoxic state.</p></sec><sec id="S31"><title>Therapy directed at the precipitating illness</title><p id="P50">The therapy is not complete unless a diagnosis of the possible
precipitating event is made and early treatment as indicated for that
underlying illness is implemented. This is not a problem in obvious cases,
when trauma, surgery, labor, or premature withdrawal of antithyroid drugs
are known to have been the precipitants of thyrotoxic crisis, and which may
require no additional management. However, when none of the latter
precipitating factors is apparent, a diligent search for some focus of
infection must be performed. Routine cultures of urine, blood, and sputum
should be obtained in the febrile thyrotoxic patient, and cultures of other
sites may be warranted on clinical grounds. Broad-spectrum antibiotic
coverage on an empiric basis may be required initially while awaiting
results of cultures.</p><p id="P51">Conditions such as ketoacidosis, pulmonary thromboembolism, or
stroke may underlie thyrotoxic crisis, particularly in the obtunded or
psychotic patient, and require the same vigorous management as routinely
indicated.</p></sec></sec><sec id="S32"><title>Prognosis</title><p id="P52">Even with early diagnosis, death can occur, and reported mortality rates
have ranged from 10% to 75% in hospitalized patients.<sup><xref rid="R85" ref-type="bibr">85</xref>,<xref rid="R116" ref-type="bibr">116</xref>,<xref rid="R117" ref-type="bibr">117</xref></sup> In most
patients who survive thyrotoxic crisis, clinical improvement is dramatic and
demonstrable within the first 24 hours. During the recovery period of the next
few days, supportive therapy such as corticosteroids, antipyretics, and
intravenous fluids may be tapered and gradually withdrawn, based on patient
status, oral intake of calories and fluids, vasomotor stability, and continuing
improvement. After the crisis has been resolved, attention may be turned to
consideration of the definitive treatment of thyrotoxicosis. Should
thyroidectomy be considered, thyrotoxicosis will need to have been adequately
treated preoperatively, to obviate any likelihood of another episode of crisis
during the surgery. Total thyroidectomy is the procedure of choice, in view of
reports of recurrent severe thyrotoxicosis and thyroid crisis after less than
total thyroidectomy.<sup><xref rid="R118" ref-type="bibr">118</xref></sup></p><p id="P53">Radioactive iodine as definitive treatment is often precluded by the
recent use of inorganic iodine in virtually all cases of storm, but it could be
considered at a later date, in which case antithyroid thionamide therapy is
continued to restore and maintain euthyroidism until such a time as ablative
therapy can be administered. Continuing treatment with antithyroid drugs alone,
in the hope of the patient&#x02019;s sustaining a spontaneous remission, is also
possible.</p></sec></sec><sec id="S33"><title>SUMMARY</title><p id="P54">The life-threatening thyroid emergencies of myxedema coma and thyrotoxic
crisis require a high index of suspicion in the appropriate clinical setting,
followed by prompt and accurate diagnosis and urgent multifaceted therapy to reduce
the risk of fatal outcome.</p></sec></body><back><fn-group><fn fn-type="COI-statement" id="FN1"><p id="P55">The authors have nothing to disclose.</p></fn></fn-group><ref-list><title>REFERENCES</title><ref id="R1"><label>1.</label><mixed-citation publication-type="journal"><name><surname>Rodriguez</surname><given-names>I</given-names></name>, <name><surname>Fluiters</surname><given-names>E</given-names></name>, <name><surname>Perez-Mendez</surname><given-names>LF</given-names></name>, <etal/>
<article-title>Factors associated with mortality of patients with myxedema coma:
prospective study in 11 cases treated in a single
institution</article-title>. <source>J Endocrinol</source>
<year>2004</year>;<volume>80</volume>:<fpage>347</fpage>&#x02013;<lpage>50</lpage>.</mixed-citation></ref><ref id="R2"><label>2.</label><mixed-citation publication-type="journal"><name><surname>Blignault</surname><given-names>EJ</given-names></name>. <article-title>Advanced pregnancy in severely myxedematous patient. A
case report and review of the literature</article-title>. <source>S Afr Med
J</source>
<year>1980</year>;<volume>57</volume>:<fpage>1050</fpage>&#x02013;<lpage>1</lpage>.<pub-id pub-id-type="pmid">7404091</pub-id></mixed-citation></ref><ref id="R3"><label>3.</label><mixed-citation publication-type="journal"><name><surname>Patel</surname><given-names>S</given-names></name>, <name><surname>Robinson</surname><given-names>S</given-names></name>, <name><surname>Bidgood</surname><given-names>RJ</given-names></name>, <etal/>
<article-title>A pre-eclamptic-like syndrome associated with hypothyroidism
during pregnancy</article-title>. <source>Q J Med</source>
<year>1991</year>;<volume>79</volume>:<fpage>435</fpage>&#x02013;<lpage>41</lpage>.<pub-id pub-id-type="pmid">1924678</pub-id></mixed-citation></ref><ref id="R4"><label>4.</label><mixed-citation publication-type="journal"><name><surname>Mathew</surname><given-names>V</given-names></name>, <name><surname>Misgar</surname><given-names>RA</given-names></name>, <name><surname>Ghosh</surname><given-names>S</given-names></name>, <etal/>
<article-title>Myxedema coma: a new look into an old crisis</article-title>.
<source>J Thyroid Res</source>
<year>2011</year>;<volume>2011</volume>:<fpage>493462</fpage>.<pub-id pub-id-type="pmid">21941682</pub-id></mixed-citation></ref><ref id="R5"><label>5.</label><mixed-citation publication-type="journal"><name><surname>Dutta</surname><given-names>P</given-names></name>, <name><surname>Bhansali</surname><given-names>A</given-names></name>, <name><surname>Masoodi</surname><given-names>SR</given-names></name>, <etal/>
<article-title>Predictors of outcome in myxedema coma: a study from a tertiary
care centre</article-title>. <source>Crit Care</source>
<year>2008</year>;<volume>12</volume>:<fpage>1</fpage>&#x02013;<lpage>8</lpage>.</mixed-citation></ref><ref id="R6"><label>6.</label><mixed-citation publication-type="journal"><name><surname>Klubo-Gwiezdzinska</surname><given-names>J</given-names></name>, <name><surname>Wartofsky</surname><given-names>L</given-names></name>. <article-title>Myxedema coma. In: Oxford textbook of endocrinology and
Diabetes. 2nd edition</article-title>. <source>Oxford: Oxford Univ.
Press</source>; <year>2011</year> p.
<fpage>537</fpage>&#x02013;<lpage>43</lpage>.</mixed-citation></ref><ref id="R7"><label>7.</label><mixed-citation publication-type="journal"><name><surname>Kwaku</surname><given-names>MP</given-names></name>, <name><surname>Burman</surname><given-names>KD</given-names></name>. <article-title>Myxedema coma</article-title>. <source>J Intensive Care
Med</source>
<year>2007</year>;<volume>22</volume>:<fpage>224</fpage>&#x02013;<lpage>31</lpage>.<pub-id pub-id-type="pmid">17712058</pub-id></mixed-citation></ref><ref id="R8"><label>8.</label><mixed-citation publication-type="journal"><name><surname>Church</surname><given-names>CO</given-names></name>, <name><surname>Callen</surname><given-names>EC</given-names></name>. <article-title>Myxedema coma associated with combination aripiprazole
and sertraline therapy</article-title>. <source>Ann Pharmacother</source>
<year>2009</year>;<volume>43</volume>:<fpage>2113</fpage>&#x02013;<lpage>6</lpage>.<pub-id pub-id-type="pmid">19934393</pub-id></mixed-citation></ref><ref id="R9"><label>9.</label><mixed-citation publication-type="journal"><name><surname>Chu</surname><given-names>M</given-names></name>, <name><surname>Seltzer</surname><given-names>TF</given-names></name>. <article-title>Myxedema coma induced by ingestion of raw bok
choy</article-title>. <source>N Engl J Med</source>
<year>2010</year>;<volume>20</volume>(<issue>362</issue>):<fpage>1945</fpage>&#x02013;<lpage>6</lpage>.</mixed-citation></ref><ref id="R10"><label>10.</label><mixed-citation publication-type="journal"><name><surname>Reinhardt</surname><given-names>W</given-names></name>, <name><surname>Mann</surname><given-names>K</given-names></name>. <article-title>Incidence, clinical picture and treatment of hypothyroid
coma. Results of a survey</article-title>. <source>Med Klin</source>
<year>1997</year>;<volume>92</volume>:<fpage>521</fpage>&#x02013;<lpage>4</lpage>.</mixed-citation></ref><ref id="R11"><label>11.</label><mixed-citation publication-type="journal"><name><surname>Jansen</surname><given-names>HJ</given-names></name>, <name><surname>Doebe</surname><given-names>SR</given-names></name>, <name><surname>Louwerse</surname><given-names>ES</given-names></name>, <etal/>
<article-title>Status epilepticus caused by a myxedema coma</article-title>.
<source>Neth J Med</source>
<year>2006</year>;<volume>64</volume>:<fpage>202</fpage>&#x02013;<lpage>5</lpage>.<pub-id pub-id-type="pmid">16788220</pub-id></mixed-citation></ref><ref id="R12"><label>12.</label><mixed-citation publication-type="journal"><name><surname>Zwillich</surname><given-names>CW</given-names></name>, <name><surname>Pierson</surname><given-names>DJ</given-names></name>, <name><surname>Hofeldt</surname><given-names>FD</given-names></name>, <etal/>
<article-title>Ventilatory control in myxedema and
hypothyroidism</article-title>. <source>N Engl J Med</source>
<year>1975</year>;<volume>292</volume>:<fpage>662</fpage>&#x02013;<lpage>5</lpage>.<pub-id pub-id-type="pmid">1113761</pub-id></mixed-citation></ref><ref id="R13"><label>13.</label><mixed-citation publication-type="journal"><name><surname>Ladenson</surname><given-names>PW</given-names></name>, <name><surname>Goldenheim</surname><given-names>PD</given-names></name>, <name><surname>Ridgway</surname><given-names>EC</given-names></name>. <article-title>Prediction of reversal of blunted respiratory
responsiveness in patients with hypothyroidism</article-title>. <source>Am J
Med</source>
<year>1988</year>;
<volume>84</volume>:<fpage>877</fpage>&#x02013;<lpage>83</lpage>.<pub-id pub-id-type="pmid">3364447</pub-id></mixed-citation></ref><ref id="R14"><label>14.</label><mixed-citation publication-type="journal"><name><surname>Birring</surname><given-names>SS</given-names></name>, <name><surname>Patel</surname><given-names>RB</given-names></name>, <name><surname>Parker</surname><given-names>D</given-names></name>, <etal/>
<article-title>Airway function and markers of airway inflammation in patients
with treated hypothyroidism</article-title>. <source>Thorax</source>
<year>2005</year>;<volume>60</volume>:<fpage>249</fpage>&#x02013;<lpage>53</lpage>.<pub-id pub-id-type="pmid">15741445</pub-id></mixed-citation></ref><ref id="R15"><label>15.</label><mixed-citation publication-type="journal"><name><surname>Schenck</surname><given-names>JB</given-names></name>, <name><surname>Rizvi</surname><given-names>AA</given-names></name>, <name><surname>Lin</surname><given-names>T</given-names></name>. <article-title>Severe primary hypothyroidism manifesting with torsades
de pointes</article-title>. <source>Am J Med Sci</source>
<year>2006</year>;<volume>331</volume>:<fpage>154</fpage>&#x02013;<lpage>6</lpage>.<pub-id pub-id-type="pmid">16538077</pub-id></mixed-citation></ref><ref id="R16"><label>16.</label><mixed-citation publication-type="journal"><name><surname>Skowsky</surname><given-names>RW</given-names></name>, <name><surname>Kikuchi</surname><given-names>TA</given-names></name>. <article-title>The role of vasopressin in the impaired water excretion
of myxedema</article-title>. <source>Am J Med</source>
<year>1978</year>;<volume>64</volume>:<fpage>613</fpage>&#x02013;<lpage>21</lpage>.<pub-id pub-id-type="pmid">645727</pub-id></mixed-citation></ref><ref id="R17"><label>17.</label><mixed-citation publication-type="journal"><name><surname>DeRubertis</surname><given-names>FR</given-names><suffix>Jr</suffix></name>, <name><surname>Michelis</surname><given-names>MF</given-names></name>, <name><surname>Bloom</surname><given-names>ME</given-names></name>, <etal/>
<article-title>Impaired water excretion in myxedema</article-title>. <source>Am
J Med</source>
<year>1971</year>;<volume>51</volume>:<fpage>41</fpage>&#x02013;<lpage>53</lpage>.<pub-id pub-id-type="pmid">5570319</pub-id></mixed-citation></ref><ref id="R18"><label>18.</label><mixed-citation publication-type="journal"><name><surname>Ardalan</surname><given-names>MR</given-names></name>, <name><surname>Ghabili</surname><given-names>K</given-names></name>, <name><surname>Mirnour</surname><given-names>R</given-names></name>, <etal/>
<article-title>Hypothyroidism-induced rhabdomyolysis and renal
failure</article-title>. <source>Ren Fail</source>
<year>2011</year>;<volume>33</volume>:<fpage>553</fpage>&#x02013;<lpage>4</lpage>.<pub-id pub-id-type="pmid">21500981</pub-id></mixed-citation></ref><ref id="R19"><label>19.</label><mixed-citation publication-type="journal"><name><surname>Nikolaidou</surname><given-names>C</given-names></name>, <name><surname>Gouridou</surname><given-names>E</given-names></name>, <name><surname>Ilonidis</surname><given-names>G</given-names></name>, <etal/>
<article-title>Acute renal dysfunction in a patient presenting with
rhabdomyolysis due to hypothyroidism attributed to Hashimoto&#x02019;s
disease</article-title>. <source>Hippokratia</source>
<year>2010</year>;<volume>4</volume>:<fpage>281</fpage>&#x02013;<lpage>3</lpage>.</mixed-citation></ref><ref id="R20"><label>20.</label><mixed-citation publication-type="journal"><name><surname>Kar</surname><given-names>PM</given-names></name>, <name><surname>Hirani</surname><given-names>A</given-names></name>, <name><surname>Allen</surname><given-names>MJ</given-names></name>. <article-title>Acute renal failure in a hypothyroid patient with
rhabdomyolysis</article-title>. <source>Clin Nephrol</source>
<year>2003</year>;<volume>60</volume>:<fpage>428</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="pmid">14690261</pub-id></mixed-citation></ref><ref id="R21"><label>21.</label><mixed-citation publication-type="journal"><name><surname>Birewar</surname><given-names>S</given-names></name>, <name><surname>Oppenheimer</surname><given-names>M</given-names></name>, <name><surname>Zawada</surname><given-names>ET</given-names><suffix>Jr</suffix></name>. <article-title>Hypothyroid acute renal failure</article-title>.
<source>S D J Med</source>
<year>2004</year>;<volume>57</volume>:<fpage>109</fpage>&#x02013;<lpage>10</lpage>.<pub-id pub-id-type="pmid">15067886</pub-id></mixed-citation></ref><ref id="R22"><label>22.</label><mixed-citation publication-type="journal"><name><surname>Ji</surname><given-names>JS</given-names></name>, <name><surname>Chae</surname><given-names>HS</given-names></name>, <name><surname>Cho</surname><given-names>YS</given-names></name>, <etal/>
<article-title>Myxedema ascites: case report and literature
review</article-title>. <source>J Korean Med Sci</source>
<year>2006</year>;<volume>21</volume>:<fpage>761</fpage>&#x02013;<lpage>4</lpage>.<pub-id pub-id-type="pmid">16891828</pub-id></mixed-citation></ref><ref id="R23"><label>23.</label><mixed-citation publication-type="journal"><name><surname>Fukunaga</surname><given-names>K</given-names></name>
<article-title>Refractory gastrointestinal bleeding treated with thyroid hormone
replacement</article-title>. <source>J Clin Gastroenterol</source>
<year>2001</year>;<volume>33</volume>:<fpage>145</fpage>&#x02013;<lpage>7</lpage>.<pub-id pub-id-type="pmid">11468443</pub-id></mixed-citation></ref><ref id="R24"><label>24.</label><mixed-citation publication-type="journal"><name><surname>Bergeron</surname><given-names>E</given-names></name>, <name><surname>Mitchell</surname><given-names>A</given-names></name>, <name><surname>Heyen</surname><given-names>F</given-names></name>, <etal/>
<article-title>Acute colonic surgery and unrecognized hypothyroidism: a warning.
Report of six cases</article-title>. <source>Dis Colon Rectum</source>
<year>1997</year>;<volume>40</volume>:<fpage>859</fpage>&#x02013;<lpage>61</lpage>.<pub-id pub-id-type="pmid">9221866</pub-id></mixed-citation></ref><ref id="R25"><label>25.</label><mixed-citation publication-type="journal"><name><surname>Manfredi</surname><given-names>E</given-names></name>, <name><surname>van Zaane</surname><given-names>B</given-names></name>, <name><surname>Gerdes</surname><given-names>VE</given-names></name>, <etal/>
<article-title>Hypothyroidism and acquired von Willebrand&#x02019;s syndrome: a
systematic review</article-title>. <source>Haemophilia</source>
<year>2008</year>;<volume>14</volume>:<fpage>423</fpage>&#x02013;<lpage>33</lpage>.<pub-id pub-id-type="pmid">18218015</pub-id></mixed-citation></ref><ref id="R26"><label>26.</label><mixed-citation publication-type="journal"><name><surname>Michiels</surname><given-names>JJ</given-names></name>, <name><surname>Schroyens</surname><given-names>W</given-names></name>, <name><surname>Berneman</surname><given-names>Z</given-names></name>, <etal/>
<article-title>Acquired von Willebrand syndrome type 1 in hypothyroidism:
reversal after treatment with thyroxine</article-title>. <source>Clin Appl
Thromb Hemost</source>
<year>2001</year>;<volume>7</volume>:<fpage>113</fpage>&#x02013;<lpage>5</lpage>.<pub-id pub-id-type="pmid">11292187</pub-id></mixed-citation></ref><ref id="R27"><label>27.</label><mixed-citation publication-type="journal"><name><surname>Hooper</surname><given-names>MJ</given-names></name>. <article-title>Diminished TSH secretion during acute non-thyroidal
illness in untreated primary hypothyroidism</article-title>.
<source>Lancet</source>
<year>1976</year>;<volume>1</volume>:<fpage>48</fpage>&#x02013;<lpage>9</lpage>.</mixed-citation></ref><ref id="R28"><label>28.</label><mixed-citation publication-type="journal"><name><surname>Wartofsky</surname><given-names>L</given-names></name>, <name><surname>Burman</surname><given-names>KD</given-names></name>. <article-title>Alterations in thyroid function in patients with
systemic illness: the &#x02018;euthyroid sick
syndrome&#x02019;</article-title>. <source>Endocr Rev</source>
<year>1982</year>;<volume>3</volume>:<fpage>164</fpage>&#x02013;<lpage>217</lpage>.<pub-id pub-id-type="pmid">6806085</pub-id></mixed-citation></ref><ref id="R29"><label>29.</label><mixed-citation publication-type="journal"><name><surname>Nicoloff</surname><given-names>JT</given-names></name>. <article-title>Thyroid storm and myxedema coma</article-title>.
<source>Med Clin North Am</source>
<year>1985</year>;<volume>69</volume>:<fpage>1005</fpage>&#x02013;<lpage>17</lpage>.<pub-id pub-id-type="pmid">2865414</pub-id></mixed-citation></ref><ref id="R30"><label>30.</label><mixed-citation publication-type="journal"><name><surname>Holvey</surname><given-names>DN</given-names></name>, <name><surname>Goodner</surname><given-names>CJ</given-names></name>, <name><surname>Nicoloff</surname><given-names>JT</given-names></name>, <etal/>
<article-title>Treatment of myxedema coma with intravenous
thyroxine</article-title>. <source>Arch Intern Med</source>
<year>1964</year>;<volume>113</volume>:<fpage>139</fpage>&#x02013;<lpage>46</lpage>.</mixed-citation></ref><ref id="R31"><label>31.</label><mixed-citation publication-type="journal"><name><surname>Ridgway</surname><given-names>EC</given-names></name>, <name><surname>McCammon</surname><given-names>JA</given-names></name>, <name><surname>Benotti</surname><given-names>J</given-names></name>, <etal/>
<article-title>Acute metabolic responses in myxedema to large doses of
intravenous l-thyroxine</article-title>. <source>Ann Intern Med</source>
<year>1972</year>;<volume>77</volume>:<fpage>549</fpage>&#x02013;<lpage>55</lpage>.<pub-id pub-id-type="pmid">4642735</pub-id></mixed-citation></ref><ref id="R32"><label>32.</label><mixed-citation publication-type="journal"><name><surname>Yamamoto</surname><given-names>T</given-names></name>, <name><surname>Fukuyama</surname><given-names>J</given-names></name>, <name><surname>Fujiyoshi</surname><given-names>A</given-names></name>. <article-title>Factors associated with mortality of myxedema coma:
report of eight cases and literature survey</article-title>.
<source>Thyroid</source>
<year>1999</year>;<volume>9</volume>:<fpage>1167</fpage>&#x02013;<lpage>74</lpage>.<pub-id pub-id-type="pmid">10646654</pub-id></mixed-citation></ref><ref id="R33"><label>33.</label><mixed-citation publication-type="journal"><name><surname>Chernow</surname><given-names>B</given-names></name>, <name><surname>Burman</surname><given-names>KD</given-names></name>, <name><surname>Johnson</surname><given-names>DL</given-names></name>, <etal/>
<article-title>T3 may be a better agent than T4 in the critically ill
hypothyroid patient: evaluation of transport across the blood-brain barrier
in a primate model</article-title>. <source>Crit Care Med</source>
<year>1983</year>;<volume>11</volume>:<fpage>99</fpage>&#x02013;<lpage>104</lpage>.<pub-id pub-id-type="pmid">6822088</pub-id></mixed-citation></ref><ref id="R34"><label>34.</label><mixed-citation publication-type="journal"><name><surname>McKerrow</surname><given-names>SD</given-names></name>, <name><surname>Osborn</surname><given-names>LA</given-names></name>, <name><surname>Levy</surname><given-names>H</given-names></name>, <etal/>
<article-title>Myxedema-associated cardiogenic shock treated with
triiodothyronine</article-title>. <source>Ann Intern Med</source>
<year>1992</year>;<volume>117</volume>:<fpage>1014</fpage>&#x02013;<lpage>5</lpage>.<pub-id pub-id-type="pmid">1443970</pub-id></mixed-citation></ref><ref id="R35"><label>35.</label><mixed-citation publication-type="journal"><name><surname>Hylander</surname><given-names>B</given-names></name>, <name><surname>Rosenqvist</surname><given-names>U</given-names></name>. <article-title>Treatment of myxedema coma: factors associated with
fatal outcome</article-title>. <source>Acta Endocrinol (Copenh)</source>
<year>1985</year>;<volume>108</volume>:<fpage>65</fpage>&#x02013;<lpage>71</lpage>.<pub-id pub-id-type="pmid">3969812</pub-id></mixed-citation></ref><ref id="R36"><label>36.</label><mixed-citation publication-type="journal"><name><surname>Wartofsky</surname><given-names>L</given-names></name>
<article-title>Myxedema coma</article-title>. <source>Endocrinol Metab Clin
North Am</source>
<year>2006</year>;<volume>35</volume>:<fpage>687</fpage>&#x02013;<lpage>98</lpage>.<pub-id pub-id-type="pmid">17127141</pub-id></mixed-citation></ref><ref id="R37"><label>37.</label><mixed-citation publication-type="journal"><name><surname>McCulloch</surname><given-names>W</given-names></name>, <name><surname>Price</surname><given-names>P</given-names></name>, <name><surname>Hinds</surname><given-names>CJ</given-names></name>, <etal/>
<article-title>Effects of low dose oral triiodothyronine in myxedema
coma</article-title>. <source>Intensive Care Med</source>
<year>1985</year>;<volume>11</volume>:<fpage>259</fpage>&#x02013;<lpage>62</lpage>.<pub-id pub-id-type="pmid">4067063</pub-id></mixed-citation></ref><ref id="R38"><label>38.</label><mixed-citation publication-type="journal"><name><surname>Vachharajani</surname><given-names>TJ</given-names></name>, <name><surname>Zaman</surname><given-names>F</given-names></name>, <name><surname>Abreo</surname><given-names>KD</given-names></name>. <article-title>Hyponatremia in critically ill patients</article-title>.
<source>J Intensive Care Med</source>
<year>2003</year>;<volume>18</volume>:<fpage>3</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="pmid">15189662</pub-id></mixed-citation></ref><ref id="R39"><label>39.</label><mixed-citation publication-type="journal"><name><surname>Pereira</surname><given-names>VG</given-names></name>, <name><surname>Haron</surname><given-names>ES</given-names></name>, <name><surname>Lima-Neto</surname><given-names>N</given-names></name>, <etal/>
<article-title>Management of myxedema coma: report on three successfully treated
cases with nasogastric or intravenous administration of
triiodothyronine</article-title>. <source>J Endocrinol Invest</source>
<year>1982</year>;<volume>5</volume>:<fpage>331</fpage>&#x02013;<lpage>4</lpage>.<pub-id pub-id-type="pmid">7153477</pub-id></mixed-citation></ref><ref id="R40"><label>40.</label><mixed-citation publication-type="journal"><name><surname>Verbalis</surname><given-names>JG</given-names></name>, <name><surname>Goldsmith</surname><given-names>SR</given-names></name>, <name><surname>Greenberg</surname><given-names>A</given-names></name>, <etal/>
<article-title>Hyponatremia treatment guidelines 2007: expert panel
recommendations</article-title>. <source>Am J Med</source>
<year>2007</year>;<volume>120</volume>:<fpage>1</fpage>&#x02013;<lpage>21</lpage>.<pub-id pub-id-type="pmid">17208069</pub-id></mixed-citation></ref><ref id="R41"><label>41.</label><mixed-citation publication-type="book"><source>Vaprisol (conivaptan HCl injection)
[package insert]</source>. <publisher-loc>Deerfield (IL)</publisher-loc>:
<publisher-name>Astellas Tokai Co</publisher-name>;
<year>2006</year>.</mixed-citation></ref><ref id="R42"><label>42.</label><mixed-citation publication-type="journal"><name><surname>Hline</surname><given-names>SS</given-names></name>, <name><surname>Pham</surname><given-names>PT</given-names></name>, <name><surname>Pham</surname><given-names>PT</given-names></name>, <etal/>
<article-title>Conivaptan: a step forward in the treatment of
hyponatremia</article-title>. <source>Ther Clin Risk Manag</source>
<year>2008</year>;<volume>4</volume>:<fpage>315</fpage>&#x02013;<lpage>26</lpage>.<pub-id pub-id-type="pmid">18728836</pub-id></mixed-citation></ref><ref id="R43"><label>43.</label><mixed-citation publication-type="journal"><name><surname>Li-Ng</surname><given-names>M</given-names></name>, <name><surname>Verbalis</surname><given-names>JG</given-names></name>. <article-title>Conivaptan: evidence supporting its therapeutic use in
hyponatremia</article-title>. <source>Core Evid</source>
<year>2010</year>;<volume>4</volume>:<fpage>83</fpage>&#x02013;<lpage>92</lpage>.<pub-id pub-id-type="pmid">20694067</pub-id></mixed-citation></ref><ref id="R44"><label>44.</label><mixed-citation publication-type="journal"><name><surname>Devdhar</surname><given-names>M</given-names></name>, <name><surname>Ousman</surname><given-names>YH</given-names></name>, <name><surname>Burman</surname><given-names>KD</given-names></name>. <article-title>Hypothyroidism</article-title>. <source>Endocrinol Metab
Clin North Am</source>
<year>2007</year>;<volume>36</volume>:<fpage>595</fpage>&#x02013;<lpage>615</lpage>.<pub-id pub-id-type="pmid">17673121</pub-id></mixed-citation></ref><ref id="R45"><label>45.</label><mixed-citation publication-type="journal"><name><surname>Jordan</surname><given-names>RM</given-names></name>. <article-title>Myxedema coma. Pathophysiology, therapy, and factors
affecting prognosis</article-title>. <source>Med Clin North Am</source>
<year>1995</year>;<volume>79</volume>:<fpage>185</fpage>&#x02013;<lpage>94</lpage>.<pub-id pub-id-type="pmid">7808091</pub-id></mixed-citation></ref><ref id="R46"><label>46.</label><mixed-citation publication-type="journal"><name><surname>Swinburne</surname><given-names>JL</given-names></name>, <name><surname>Kreisman</surname><given-names>SH</given-names></name>. <article-title>A rare case of subacute thyroiditis causing thyroid
storm</article-title>. <source>Thyroid</source>
<year>2007</year>;<volume>17</volume>:<fpage>73</fpage>&#x02013;<lpage>6</lpage>.<pub-id pub-id-type="pmid">17274754</pub-id></mixed-citation></ref><ref id="R47"><label>47.</label><mixed-citation publication-type="journal"><name><surname>Yoon</surname><given-names>SJ</given-names></name>, <name><surname>Choi</surname><given-names>SR</given-names></name>, <name><surname>Kim</surname><given-names>DM</given-names></name>, <etal/>
<article-title>A case of thyroid storm due to thyrotoxicosis
factitia</article-title>. <source>Yonsei Med J</source>
<year>2003</year>;<volume>44</volume>:<fpage>351</fpage>&#x02013;<lpage>4</lpage>.<pub-id pub-id-type="pmid">12728481</pub-id></mixed-citation></ref><ref id="R48"><label>48.</label><mixed-citation publication-type="book"><name><surname>Klubo-Gwiezdzinska</surname><given-names>J</given-names></name>, <name><surname>Wartofsky</surname><given-names>L</given-names></name>. <chapter-title>Thyrotoxic storm</chapter-title>
<source>In: Oxford
textbook of endocrinology and diabetes</source>. <edition>2nd</edition>
edition. <publisher-name>Oxford: Oxford Univ. Press</publisher-name>;
<year>2011</year> p.
<fpage>454</fpage>&#x02013;<lpage>61</lpage>.</mixed-citation></ref><ref id="R49"><label>49.</label><mixed-citation publication-type="journal"><name><surname>Tewari</surname><given-names>K</given-names></name>, <name><surname>Balderston</surname><given-names>KD</given-names></name>, <name><surname>Carpenter</surname><given-names>SE</given-names></name>, <etal/>
<article-title>Papillary thyroid carcinoma manifesting as thyroid storm of
pregnancy: case report</article-title>. <source>Am J Obstet Gynecol</source>
<year>1998</year>;
<volume>179</volume>:<fpage>818</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="pmid">9757998</pub-id></mixed-citation></ref><ref id="R50"><label>50.</label><mixed-citation publication-type="journal"><name><surname>McDermott</surname><given-names>MT</given-names></name>, <name><surname>Kidd</surname><given-names>GS</given-names></name>, <name><surname>Dodson</surname><given-names>LE</given-names></name>, <etal/>
<article-title>Radioiodine-induced thyroid storm</article-title>. <source>Am J
Med</source>
<year>1983</year>;<volume>75</volume>:<fpage>353</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="pmid">6349350</pub-id></mixed-citation></ref><ref id="R51"><label>51.</label><mixed-citation publication-type="journal"><name><surname>Naito</surname><given-names>Y</given-names></name>, <name><surname>Sone</surname><given-names>T</given-names></name>, <name><surname>Kataoka</surname><given-names>K</given-names></name>, <etal/>
<article-title>Thyroid storm due to functioning metastatic thyroid carcinoma in
a burn patient</article-title>. <source>Anesthesiology</source>
<year>1997</year>;<volume>87</volume>:<fpage>433</fpage>&#x02013;<lpage>5</lpage>.<pub-id pub-id-type="pmid">9286911</pub-id></mixed-citation></ref><ref id="R52"><label>52.</label><mixed-citation publication-type="journal"><name><surname>Al-Anazi</surname><given-names>KA</given-names></name>, <name><surname>Inam</surname><given-names>S</given-names></name>, <name><surname>Jeha</surname><given-names>MT</given-names></name>, <etal/>
<article-title>Thyrotoxic crisis induced by cytotoxic
chemotherapy</article-title>. <source>Support Care Cancer</source>
<year>2005</year>;<volume>13</volume>:<fpage>196</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="pmid">15459765</pub-id></mixed-citation></ref><ref id="R53"><label>53.</label><mixed-citation publication-type="journal"><name><surname>Sebe</surname><given-names>A</given-names></name>, <name><surname>Satar</surname><given-names>S</given-names></name>, <name><surname>Sari</surname><given-names>A</given-names></name>. <article-title>Thyroid storm induced by aspirin intoxication and the
effect of hemodialysis: a case report</article-title>. <source>Adv
Ther</source>
<year>2004</year>;<volume>21</volume>:<fpage>173</fpage>&#x02013;<lpage>7</lpage>.<pub-id pub-id-type="pmid">15509133</pub-id></mixed-citation></ref><ref id="R54"><label>54.</label><mixed-citation publication-type="journal"><name><surname>Hirvonen</surname><given-names>EA</given-names></name>, <name><surname>Niskanen</surname><given-names>LK</given-names></name>, <name><surname>Niskanen</surname><given-names>MM</given-names></name>. <article-title>Thyroid storm prior to induction of
anaesthesia</article-title>. <source>Anaesthesia</source>
<year>2004</year>;<volume>59</volume>:<fpage>1020</fpage>&#x02013;<lpage>2</lpage>.<pub-id pub-id-type="pmid">15488064</pub-id></mixed-citation></ref><ref id="R55"><label>55.</label><mixed-citation publication-type="journal"><name><surname>Yuan</surname><given-names>YD</given-names></name>, <name><surname>Seak</surname><given-names>CJ</given-names></name>, <name><surname>Lin</surname><given-names>CC</given-names></name>, <etal/>
<article-title>Thyroid storm precipitated by organophosphate
intoxication</article-title>. <source>Am J Emerg Med</source>
<year>2007</year>;<volume>25</volume>:<fpage>861</fpage>.</mixed-citation></ref><ref id="R56"><label>56.</label><mixed-citation publication-type="journal"><name><surname>Samaras</surname><given-names>K</given-names></name>, <name><surname>Marel</surname><given-names>GM</given-names></name>. <article-title>Failure of plasmapheresis, corticosteroids and
thionamides to ameliorate a case of protracted amiodarone-induced
thyroiditis</article-title>. <source>Clin Endocrinol</source>
<year>1996</year>;<volume>45</volume>:<fpage>365</fpage>&#x02013;<lpage>8</lpage>.</mixed-citation></ref><ref id="R57"><label>57.</label><mixed-citation publication-type="journal"><name><surname>Noh</surname><given-names>KW</given-names></name>, <name><surname>Seon</surname><given-names>CS</given-names></name>, <name><surname>Choi</surname><given-names>JW</given-names></name>, <etal/>
<article-title>Thyroid storm and reversible thyrotoxic cardiomyopathy after
ingestion of seafood stew thought to contain marine
neurotoxin</article-title>. <source>Thyroid</source>
<year>2011</year>;<volume>21</volume>:<fpage>679</fpage>&#x02013;<lpage>82</lpage>.<pub-id pub-id-type="pmid">21563915</pub-id></mixed-citation></ref><ref id="R58"><label>58.</label><mixed-citation publication-type="journal"><name><surname>Riis</surname><given-names>AL</given-names></name>, <name><surname>Gravholt</surname><given-names>CH</given-names></name>, <name><surname>Djurhuus</surname><given-names>CB</given-names></name>, <etal/>
<article-title>Elevated regional lipolysis in hyperthyroidism</article-title>.
<source>J Clin Endocrinol Metab</source>
<year>2002</year>;<volume>87</volume>:<fpage>4747</fpage>&#x02013;<lpage>53</lpage>.<pub-id pub-id-type="pmid">12364469</pub-id></mixed-citation></ref><ref id="R59"><label>59.</label><mixed-citation publication-type="journal"><name><surname>Aiello</surname><given-names>DP</given-names></name>, <name><surname>DuPlessis</surname><given-names>AJ</given-names></name>, <name><surname>Pattishall</surname><given-names>EG</given-names><suffix>III</suffix></name>, <etal/>
<article-title>Thyroid storm presenting with coma and seizures</article-title>.
<source>Clin Pediatr (Phila)</source>
<year>1989</year>;<volume>28</volume>:<fpage>571</fpage>&#x02013;<lpage>4</lpage>.<pub-id pub-id-type="pmid">2582697</pub-id></mixed-citation></ref><ref id="R60"><label>60.</label><mixed-citation publication-type="journal"><name><surname>Lee</surname><given-names>TG</given-names></name>, <name><surname>Ha</surname><given-names>CK</given-names></name>, <name><surname>Lim</surname><given-names>BH</given-names></name>. <article-title>Thyroid storm presenting as status epilepticus and
stroke</article-title>. <source>Postgrad Med J</source>
<year>1997</year>;<volume>73</volume>:<fpage>61</fpage>.</mixed-citation></ref><ref id="R61"><label>61.</label><mixed-citation publication-type="journal"><name><surname>Dai</surname><given-names>A</given-names></name>, <name><surname>Wasay</surname><given-names>M</given-names></name>, <name><surname>Dubey</surname><given-names>N</given-names></name>, <etal/>
<article-title>Superior sagittal sinus thrombosis secondary to
hyperthyroidism</article-title>. <source>J Stroke Cerebrovasc Dis</source>
<year>2000</year>;<volume>9</volume>:<fpage>89</fpage>&#x02013;<lpage>90</lpage>.<pub-id pub-id-type="pmid">17895204</pub-id></mixed-citation></ref><ref id="R62"><label>62.</label><mixed-citation publication-type="journal"><name><surname>Lu</surname><given-names>KC</given-names></name>, <name><surname>Hsu</surname><given-names>YJ</given-names></name>, <name><surname>Chiu</surname><given-names>JS</given-names></name>, <etal/>
<article-title>Effects of potassium supplementation on the recovery of
thyrotoxic periodic paralysis</article-title>. <source>Am J Emerg
Med</source>
<year>2004</year>;<volume>22</volume>:<fpage>544</fpage>&#x02013;<lpage>7</lpage>.<pub-id pub-id-type="pmid">15666258</pub-id></mixed-citation></ref><ref id="R63"><label>63.</label><mixed-citation publication-type="journal"><name><surname>Feroza</surname><given-names>M</given-names></name>, <name><surname>May</surname><given-names>H</given-names></name>. <article-title>Apathetic thyrotoxicosis</article-title>. <source>Int J
Clin Pract</source>
<year>1997</year>;<volume>51</volume>:<fpage>332</fpage>&#x02013;<lpage>3</lpage>.<pub-id pub-id-type="pmid">9489099</pub-id></mixed-citation></ref><ref id="R64"><label>64.</label><mixed-citation publication-type="journal"><name><surname>Jao</surname><given-names>YT</given-names></name>, <name><surname>Chen</surname><given-names>Y</given-names></name>, <name><surname>Lee</surname><given-names>WH</given-names></name>, <etal/>
<article-title>Thyroid storm and ventricular tachycardia</article-title>.
<source>South Med J</source>
<year>2004</year>;<volume>976</volume>:<fpage>604</fpage>&#x02013;<lpage>7</lpage>.</mixed-citation></ref><ref id="R65"><label>65.</label><mixed-citation publication-type="journal"><name><surname>Daly</surname><given-names>MJ</given-names></name>, <name><surname>Wilson</surname><given-names>CM</given-names></name>, <name><surname>Dolan</surname><given-names>SJ</given-names></name>, <etal/>
<article-title>Reversible dilated cardiomyopathy associated with post-partum
thyrotoxic storm</article-title>. <source>QJM</source>
<year>2009</year>;<volume>102</volume>:<fpage>217</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="pmid">19141496</pub-id></mixed-citation></ref><ref id="R66"><label>66.</label><mixed-citation publication-type="journal"><name><surname>Opdahl</surname><given-names>H</given-names></name>, <name><surname>Eritsland</surname><given-names>J</given-names></name>, <name><surname>Sovik</surname><given-names>E</given-names></name>. <article-title>Acute myocardial infarction and thyrotoxic
storm&#x02014;a difficult and dangerous combination</article-title>.
<source>Acta Anaesthesiol Scand</source>
<year>2005</year>;<volume>49</volume>:<fpage>707</fpage>&#x02013;<lpage>11</lpage>.<pub-id pub-id-type="pmid">15836689</pub-id></mixed-citation></ref><ref id="R67"><label>67.</label><mixed-citation publication-type="journal"><name><surname>Lee</surname><given-names>SM</given-names></name>, <name><surname>Jung</surname><given-names>TS</given-names></name>, <name><surname>Hahm</surname><given-names>JR</given-names></name>, <etal/>
<article-title>Thyrotoxicosis with coronary spasm that required coronary artery
bypass surgery</article-title>. <source>Intern Med</source>
<year>2007</year>;<volume>46</volume>:<fpage>1915</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="pmid">18057764</pub-id></mixed-citation></ref><ref id="R68"><label>68.</label><mixed-citation publication-type="journal"><name><surname>Liu</surname><given-names>YC</given-names></name>, <name><surname>Tsai</surname><given-names>WS</given-names></name>, <name><surname>Chau</surname><given-names>T</given-names></name>, <etal/>
<article-title>Acute hypercapnic respiratory failure due to thyrotoxic periodic
paralysis</article-title>. <source>Am J Med Sci</source>
<year>2004</year>;<volume>327</volume>:<fpage>264</fpage>&#x02013;<lpage>7</lpage>.<pub-id pub-id-type="pmid">15166747</pub-id></mixed-citation></ref><ref id="R69"><label>69.</label><mixed-citation publication-type="journal"><name><surname>Mezosi</surname><given-names>E</given-names></name>, <name><surname>Szabo</surname><given-names>J</given-names></name>, <name><surname>Nagy</surname><given-names>EV</given-names></name>, <etal/>
<article-title>Nongenomic effect of thyroid hormone on free-radical production
in human polymorphonuclear leukocytes</article-title>. <source>J
Endocrinol</source>
<year>2005</year>;<volume>185</volume>:<fpage>121</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="pmid">15817833</pub-id></mixed-citation></ref><ref id="R70"><label>70.</label><mixed-citation publication-type="journal"><name><surname>Luong</surname><given-names>KV</given-names></name>, <name><surname>Nguyen</surname><given-names>LT</given-names></name>. <article-title>Hyperthyroidism and asthma</article-title>. <source>J
Asthma</source>
<year>2000</year>;<volume>37</volume>:<fpage>125</fpage>&#x02013;<lpage>30</lpage>.<pub-id pub-id-type="pmid">10805201</pub-id></mixed-citation></ref><ref id="R71"><label>71.</label><mixed-citation publication-type="journal"><name><surname>Barczynski</surname><given-names>M</given-names></name>, <name><surname>Thor</surname><given-names>P</given-names></name>. <article-title>Reversible autonomic dysfunction in hyperthyroid
patients affects gastric myoelectrical activity and
emptying</article-title>. <source>Clin Auton Res</source>
<year>2001</year>;<volume>114</volume>:<fpage>243</fpage>&#x02013;<lpage>9</lpage>.</mixed-citation></ref><ref id="R72"><label>72.</label><mixed-citation publication-type="journal"><name><surname>Bhattacharyya</surname><given-names>A</given-names></name>, <name><surname>Wiles</surname><given-names>PG</given-names></name>. <article-title>Thyrotoxic crisis presenting as acute
abdomen</article-title>. <source>J R Soc Med</source>
<year>1997</year>;<volume>90</volume>:<fpage>681</fpage>&#x02013;<lpage>2</lpage>.<pub-id pub-id-type="pmid">9496295</pub-id></mixed-citation></ref><ref id="R73"><label>73.</label><mixed-citation publication-type="journal"><name><surname>Cansler</surname><given-names>CL</given-names></name>, <name><surname>Latham</surname><given-names>JA</given-names></name>, <name><surname>Brown</surname><given-names>PM</given-names><suffix>Jr</suffix></name>, <etal/>
<article-title>Duodenal obstruction in thyroid storm</article-title>.
<source>South Med J</source>
<year>1997</year>;<volume>90</volume>:<fpage>1143</fpage>&#x02013;<lpage>6</lpage>.<pub-id pub-id-type="pmid">9386060</pub-id></mixed-citation></ref><ref id="R74"><label>74.</label><mixed-citation publication-type="journal"><name><surname>Leow</surname><given-names>MK</given-names></name>, <name><surname>Chew</surname><given-names>DE</given-names></name>, <name><surname>Zhu</surname><given-names>M</given-names></name>, <etal/>
<article-title>Thyrotoxicosis and acute abdomen: still as defying and
misunderstood today? Brief observations over the recent
decade</article-title>. <source>QJM</source>
<year>2008</year>;<volume>101</volume>:<fpage>943</fpage>&#x02013;<lpage>7</lpage>.<pub-id pub-id-type="pmid">18784193</pub-id></mixed-citation></ref><ref id="R75"><label>75.</label><mixed-citation publication-type="journal"><name><surname>van Hoek</surname><given-names>I</given-names></name>, <name><surname>Daminet</surname><given-names>S</given-names></name>. <article-title>Interactions between thyroid and kidney function in
pathological conditions of these organ systems: a review</article-title>.
<source>Gen Comp Endocrinol</source>
<year>2008</year>;<volume>160</volume>:<fpage>205</fpage>&#x02013;<lpage>15</lpage>.<pub-id pub-id-type="pmid">19133263</pub-id></mixed-citation></ref><ref id="R76"><label>76.</label><mixed-citation publication-type="journal"><name><surname>Goswami</surname><given-names>R</given-names></name>, <name><surname>Seth</surname><given-names>A</given-names></name>, <name><surname>Goswami</surname><given-names>AK</given-names></name>, <etal/>
<article-title>Prevalence of enuresis and other bladder symptoms in patients
with active Graves&#x02019; disease</article-title>. <source>Br J
Urol</source>
<year>1997</year>;
<volume>804</volume>:<fpage>563</fpage>&#x02013;<lpage>6</lpage>.</mixed-citation></ref><ref id="R77"><label>77.</label><mixed-citation publication-type="journal"><name><surname>Kahara</surname><given-names>T</given-names></name>, <name><surname>Yoshizawa</surname><given-names>M</given-names></name>, <name><surname>Nakaya</surname><given-names>I</given-names></name>, <etal/>
<article-title>Thyroid crisis following interstitial nephritis</article-title>.
<source>Intern Med</source>
<year>2008</year>;<volume>47</volume>:<fpage>1237</fpage>&#x02013;<lpage>40</lpage>.<pub-id pub-id-type="pmid">18591847</pub-id></mixed-citation></ref><ref id="R78"><label>78.</label><mixed-citation publication-type="journal"><name><surname>Homonick</surname><given-names>M</given-names></name>, <name><surname>Gessl</surname><given-names>A</given-names></name>, <name><surname>Ferlitsch</surname><given-names>A</given-names></name>, <etal/>
<article-title>Altered platelet plug formation in hyperthyroidism and
hypothyroidism</article-title>. <source>J Clin Endocrinol Metab</source>
<year>2007</year>;<volume>92</volume>:<fpage>3006</fpage>&#x02013;<lpage>12</lpage>.<pub-id pub-id-type="pmid">17488803</pub-id></mixed-citation></ref><ref id="R79"><label>79.</label><mixed-citation publication-type="journal"><name><surname>Romualdi</surname><given-names>E</given-names></name>, <name><surname>Squizzato</surname><given-names>A</given-names></name>, <name><surname>Ageno</surname><given-names>W</given-names></name>. <article-title>Venous thrombosis: a possible complication of overt
hyperthyroidism</article-title>. <source>Eur J Intern Med</source>
<year>2008</year>;<volume>19</volume>:<fpage>386</fpage>&#x02013;<lpage>7</lpage>.</mixed-citation></ref><ref id="R80"><label>80.</label><mixed-citation publication-type="journal"><name><surname>Pekdemir</surname><given-names>M</given-names></name>, <name><surname>Yilmaz</surname><given-names>S</given-names></name>, <name><surname>Ersel</surname><given-names>M</given-names></name>, <etal/>
<article-title>A rare cause of headache; cerebral venous sinus thrombosis due to
hyperthyroidism</article-title>. <source>Am J Emerg Med</source>
<year>2008</year>;<volume>26</volume>:<fpage>383</fpage>.</mixed-citation></ref><ref id="R81"><label>81.</label><mixed-citation publication-type="journal"><name><surname>Osman</surname><given-names>F</given-names></name>, <name><surname>Gamma</surname><given-names>MD</given-names></name>, <name><surname>Sheppard</surname><given-names>MC</given-names></name>, <etal/>
<article-title>Clinical review 142: cardiac dysrhythmias and thyroid
dysfunction: the hidden menace?</article-title>
<source>J Clin Endocrinol Metab</source>
<year>2002</year>;<volume>87</volume>:<fpage>963</fpage>&#x02013;<lpage>7</lpage>.<pub-id pub-id-type="pmid">11889143</pub-id></mixed-citation></ref><ref id="R82"><label>82.</label><mixed-citation publication-type="journal"><name><surname>Squizzato</surname><given-names>A</given-names></name>, <name><surname>Gerdes</surname><given-names>VE</given-names></name>. <article-title>Thyroid disease and haemostasis: a relationship with
clinical implications?</article-title>
<source>Thromb Haemost</source>
<year>2008</year>;<volume>100</volume>:<fpage>727</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="pmid">18989507</pub-id></mixed-citation></ref><ref id="R83"><label>83.</label><mixed-citation publication-type="journal"><name><surname>Lippi</surname><given-names>G</given-names></name>, <name><surname>Franchini</surname><given-names>M</given-names></name>, <name><surname>Targher</surname><given-names>G</given-names></name>, <etal/>
<article-title>Hyperthyroidism is associated with shortened APTT and increased
fibrinogen values in a general population of unselected
outpatients</article-title>. <source>J Thromb Thrombolysis</source>
<year>2008</year>;<volume>28</volume>:<fpage>362</fpage>&#x02013;<lpage>5</lpage>.<pub-id pub-id-type="pmid">18787930</pub-id></mixed-citation></ref><ref id="R84"><label>84.</label><mixed-citation publication-type="book"><name><surname>Wartofsky</surname><given-names>L</given-names></name>
<chapter-title>The low T3 or &#x02018;sick euthyroid
syndrome&#x02019;</chapter-title>: update 1994. In: <name><surname>Braverman</surname><given-names>LE</given-names></name>, <name><surname>Refetoff</surname><given-names>S</given-names></name>, editors. <source>Endocrine Reviews monographs. 3. Clinical and
molecular aspects of diseases of the thyroid</source>.
<publisher-loc>Bethesda (MD)</publisher-loc>: <publisher-name>The Endocrine
Society</publisher-name>; <year>1994</year> p.
<fpage>248</fpage>&#x02013;<lpage>51</lpage>.</mixed-citation></ref><ref id="R85"><label>85.</label><mixed-citation publication-type="journal"><name><surname>Burch</surname><given-names>HB</given-names></name>, <name><surname>Wartofsky</surname><given-names>L</given-names></name>. <article-title>Life-threatening thyrotoxicosis. Thyroid
storm</article-title>. <source>Endocrinol Metab Clin North Am</source>
<year>1993</year>;<volume>22</volume>:<fpage>263</fpage>&#x02013;<lpage>77</lpage>.<pub-id pub-id-type="pmid">8325286</pub-id></mixed-citation></ref><ref id="R86"><label>86.</label><mixed-citation publication-type="journal"><name><surname>Kobayashi</surname><given-names>C</given-names></name>, <name><surname>Sasaki</surname><given-names>H</given-names></name>, <name><surname>Kosuge</surname><given-names>K</given-names></name>, <etal/>
<article-title>Severe starvation hypoglycemia and congestive heart failure
induced by thyroid crisis, with accidentally induced severe liver
dysfunction and disseminated intravascular coagulation</article-title>.
<source>Intern Med</source>
<year>2005</year>;<volume>44</volume>:<fpage>234</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="pmid">15805713</pub-id></mixed-citation></ref><ref id="R87"><label>87.</label><mixed-citation publication-type="journal"><name><surname>Bahn Chair</surname><given-names>RS</given-names></name>, <name><surname>Burch</surname><given-names>HB</given-names></name>, <name><surname>Cooper</surname><given-names>DS</given-names></name>, <etal/>
<article-title>American Thyroid Association; American Association of Clinical
Endocrinologists. Hyperthyroidism and other causes of thyrotoxicosis:
management guidelines of the American Thyroid Association and American
Association of Clinical Endocrinologists</article-title>.
<source>Thyroid</source>
<year>2011</year>;<volume>21</volume>:<fpage>593</fpage>&#x02013;<lpage>646</lpage>.<pub-id pub-id-type="pmid">21510801</pub-id></mixed-citation></ref><ref id="R88"><label>88.</label><mixed-citation publication-type="journal"><name><surname>Nareem</surname><given-names>N</given-names></name>, <name><surname>Miner</surname><given-names>DJ</given-names></name>, <name><surname>Amatruda</surname><given-names>JM</given-names></name>. <article-title>Methimazole: an alternative route of
administration</article-title>. <source>J Clin Endocrinol Metab</source>
<year>1982</year>;<volume>54</volume>:<fpage>180</fpage>&#x02013;<lpage>1</lpage>.<pub-id pub-id-type="pmid">7054215</pub-id></mixed-citation></ref><ref id="R89"><label>89.</label><mixed-citation publication-type="journal"><name><surname>Yeung</surname><given-names>SC</given-names></name>, <name><surname>Go</surname><given-names>R</given-names></name>, <name><surname>Balasubramanyam</surname><given-names>A</given-names></name>. <article-title>Rectal administration of iodide and propylthiouracil in
the treatment of thyroid storm</article-title>. <source>Thyroid</source>
<year>1995</year>;<volume>5</volume>:<fpage>403</fpage>&#x02013;<lpage>5</lpage>.<pub-id pub-id-type="pmid">8563481</pub-id></mixed-citation></ref><ref id="R90"><label>90.</label><mixed-citation publication-type="journal"><name><surname>Zweig</surname><given-names>SB</given-names></name>, <name><surname>Schlosser</surname><given-names>JR</given-names></name>, <name><surname>Thomas</surname><given-names>SA</given-names></name>, <etal/>
<article-title>Rectal administration of propylthiouracil in suppository form in
patients with thyrotoxicosis and critical illness: case report and review of
literature</article-title>. <source>Endocr Pract</source>
<year>2006</year>;<volume>12</volume>:<fpage>43</fpage>&#x02013;<lpage>7</lpage>.</mixed-citation></ref><ref id="R91"><label>91.</label><mixed-citation publication-type="journal"><name><surname>Ogiso</surname><given-names>S</given-names></name>, <name><surname>Inamoto</surname><given-names>S</given-names></name>, <name><surname>Hata</surname><given-names>H</given-names></name>, <etal/>
<article-title>Successful treatment of gastric perforation with thyrotoxic
crisis</article-title>. <source>Am J Emerg Med</source>
<year>2008</year>;<volume>26</volume>:<fpage>3</fpage>&#x02013;<lpage>4</lpage>.</mixed-citation></ref><ref id="R92"><label>92.</label><mixed-citation publication-type="journal"><name><surname>Thomas</surname><given-names>DJ</given-names></name>, <name><surname>Hardy</surname><given-names>J</given-names></name>, <name><surname>Sarwar</surname><given-names>R</given-names></name>, <etal/>
<article-title>Thyroid storm treated with intravenous methimazole in patients
with gastrointestinal dysfunction</article-title>. <source>Br J Hosp Med
(Lond)</source>
<year>2006</year>;<volume>67</volume>:<fpage>492</fpage>&#x02013;<lpage>3</lpage>.<pub-id pub-id-type="pmid">17017621</pub-id></mixed-citation></ref><ref id="R93"><label>93.</label><mixed-citation publication-type="journal"><name><surname>Weissel</surname><given-names>M</given-names></name>
<article-title>Withdrawal of the parenterally applicable form of thyrostatic
drugs in Austria</article-title>. <source>Thyroid</source>
<year>2005</year>;<volume>15</volume>:<fpage>1203</fpage>.</mixed-citation></ref><ref id="R94"><label>94.</label><mixed-citation publication-type="journal"><name><surname>Sowi&#x00144;ski</surname><given-names>J</given-names></name>, <name><surname>Junik</surname><given-names>R</given-names></name>, <name><surname>Gembicki</surname><given-names>M</given-names></name>. <article-title>Effectiveness of intravenous administration of
methimazole in patients with thyroid crisis</article-title>.
<source>Endokrynol Pol</source>
<year>1988</year>;<volume>39</volume>:<fpage>67</fpage>&#x02013;<lpage>73</lpage>.<pub-id pub-id-type="pmid">3224594</pub-id></mixed-citation></ref><ref id="R95"><label>95.</label><mixed-citation publication-type="journal"><name><surname>Wartofsky</surname><given-names>L</given-names></name>, <name><surname>Ransil</surname><given-names>BJ</given-names></name>, <name><surname>Ingbar</surname><given-names>SH</given-names></name>. <article-title>Inhibition by iodine of the release of thyroxine from
the thyroid glands of patients with thyrotoxicosis</article-title>.
<source>J Clin Invest</source>
<year>1970</year>;<volume>49</volume>:<fpage>78</fpage>&#x02013;<lpage>86</lpage>.<pub-id pub-id-type="pmid">5409810</pub-id></mixed-citation></ref><ref id="R96"><label>96.</label><mixed-citation publication-type="journal"><name><surname>Boehm</surname><given-names>TM</given-names></name>, <name><surname>Burman</surname><given-names>KD</given-names></name>, <name><surname>Barnes</surname><given-names>S</given-names></name>, <etal/>
<article-title>Lithium and iodine combination therapy for
thyrotoxicosis</article-title>. <source>Acta Endocrinol (Copenh)</source>
<year>1980</year>;<volume>94</volume>:<fpage>174</fpage>&#x02013;<lpage>83</lpage>.<pub-id pub-id-type="pmid">7415757</pub-id></mixed-citation></ref><ref id="R97"><label>97.</label><mixed-citation publication-type="journal"><name><surname>Reed</surname><given-names>J</given-names></name>, <name><surname>Bradley</surname><given-names>EL</given-names><suffix>III</suffix></name>. <article-title>Postoperative thyroid storm after lithium
preparation</article-title>. <source>Surgery</source>
<year>1985</year>;<volume>98</volume>:<fpage>983</fpage>&#x02013;<lpage>6</lpage>.<pub-id pub-id-type="pmid">3933136</pub-id></mixed-citation></ref><ref id="R98"><label>98.</label><mixed-citation publication-type="journal"><name><surname>Vyas</surname><given-names>AA</given-names></name>, <name><surname>Vyas</surname><given-names>P</given-names></name>, <name><surname>Fillipon</surname><given-names>NL</given-names></name>, <etal/>
<article-title>Successful treatment of thyroid storm with plasmapheresis in a
patient with methimazole-induced agranulocytosis</article-title>.
<source>Endocr Pract</source>
<year>2010</year>;<volume>16</volume>:<fpage>673</fpage>&#x02013;<lpage>6</lpage>.<pub-id pub-id-type="pmid">20439250</pub-id></mixed-citation></ref><ref id="R99"><label>99.</label><mixed-citation publication-type="journal"><name><surname>Ozbey</surname><given-names>N</given-names></name>, <name><surname>Kalayoglu-Besisik</surname><given-names>S</given-names></name>, <name><surname>Gul</surname><given-names>N</given-names></name>, <etal/>
<article-title>Therapeutic plasmapheresis in patients with severe
hyperthyroidism in whom antithyroid drugs are
contraindicated</article-title>. <source>Int J Clin Pract</source>
<year>2004</year>;<volume>58</volume>:<fpage>554</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="pmid">15311553</pub-id></mixed-citation></ref><ref id="R100"><label>100.</label><mixed-citation publication-type="journal"><name><surname>Ezer</surname><given-names>A</given-names></name>, <name><surname>Caliskan</surname><given-names>K</given-names></name>, <name><surname>Parlakgumus</surname><given-names>A</given-names></name>, <etal/>
<article-title>Preoperative therapeutic plasma exchange in patients with
thyrotoxicosis</article-title>. <source>J Clin Apher</source>
<year>2009</year>;<volume>24</volume>:<fpage>111</fpage>&#x02013;<lpage>4</lpage>.<pub-id pub-id-type="pmid">19484727</pub-id></mixed-citation></ref><ref id="R101"><label>101.</label><mixed-citation publication-type="journal"><name><surname>Enghofer</surname><given-names>M</given-names></name>, <name><surname>Badenhoop</surname><given-names>K</given-names></name>, <name><surname>Zeuzem</surname><given-names>S</given-names></name>, <etal/>
<article-title>Fulminant hepatitis A in a patient with severe hyperthyroidism;
rapid recovery from hepatic coma after plasmapheresis and total
thyroidectomy</article-title>. <source>J Clin Endocrinol Metab</source>
<year>2000</year>;<volume>85</volume>:<fpage>1765</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="pmid">10843149</pub-id></mixed-citation></ref><ref id="R102"><label>102.</label><mixed-citation publication-type="journal"><name><surname>Burman</surname><given-names>KD</given-names></name>, <name><surname>Yeager</surname><given-names>HC</given-names></name>, <name><surname>Briggs</surname><given-names>WA</given-names></name>, <etal/>
<article-title>Resin hemoperfusion: a method of removing circulating thyroid
hormones</article-title>. <source>J Clin Endocrinol Metab</source>
<year>1976</year>;<volume>42</volume>:<fpage>70</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="pmid">55416</pub-id></mixed-citation></ref><ref id="R103"><label>103.</label><mixed-citation publication-type="journal"><name><surname>Candrina</surname><given-names>R</given-names></name>, <name><surname>DiStefano</surname><given-names>O</given-names></name>, <name><surname>Spandrio</surname><given-names>S</given-names></name>, <etal/>
<article-title>Treatment of thyrotoxic storm by charcoal
plasmaperfusion</article-title>. <source>J Endocrinol Invest</source>
<year>1989</year>;<volume>12</volume>:<fpage>133</fpage>&#x02013;<lpage>4</lpage>.</mixed-citation></ref><ref id="R104"><label>104.</label><mixed-citation publication-type="journal"><name><surname>Solomon</surname><given-names>BL</given-names></name>, <name><surname>Wartofsky</surname><given-names>L</given-names></name>, <name><surname>Burman</surname><given-names>KD</given-names></name>. <article-title>Adjunctive cholestyramine therapy for
thyrotoxicosis</article-title>. <source>Clin Endocrinol (Oxf)</source>
<year>1993</year>;<volume>38</volume>:<fpage>39</fpage>&#x02013;<lpage>43</lpage>.<pub-id pub-id-type="pmid">8435884</pub-id></mixed-citation></ref><ref id="R105"><label>105.</label><mixed-citation publication-type="journal"><name><surname>Hughes</surname><given-names>G</given-names></name>
<article-title>Management of thyrotoxic crisis with a beta-adrenergic blocking
agent (pronethalol)</article-title>. <source>Br J Clin Pract</source>
<year>1966</year>;<volume>20</volume>:<fpage>579</fpage>&#x02013;<lpage>81</lpage>.<pub-id pub-id-type="pmid">4382688</pub-id></mixed-citation></ref><ref id="R106"><label>106.</label><mixed-citation publication-type="journal"><name><surname>Feely</surname><given-names>J</given-names></name>, <name><surname>Forrest</surname><given-names>A</given-names></name>, <name><surname>Gunn</surname><given-names>A</given-names></name>, <etal/>
<article-title>Propranolol dosage in thyrotoxicosis</article-title>. <source>J
Clin Endocrinol Metab</source>
<year>1980</year>;<volume>51</volume>:<fpage>658</fpage>&#x02013;<lpage>61</lpage>.<pub-id pub-id-type="pmid">7410541</pub-id></mixed-citation></ref><ref id="R107"><label>107.</label><mixed-citation publication-type="journal"><name><surname>Rubenfeld</surname><given-names>S</given-names></name>, <name><surname>Silverman</surname><given-names>VE</given-names></name>, <name><surname>Welch</surname><given-names>KM</given-names></name>, <etal/>
<article-title>Variable plasma propranolol levels in
thyrotoxicosis</article-title>. <source>N Engl J Med</source>
<year>1979</year>;<volume>300</volume>:<fpage>353</fpage>&#x02013;<lpage>4</lpage>.<pub-id pub-id-type="pmid">759897</pub-id></mixed-citation></ref><ref id="R108"><label>108.</label><mixed-citation publication-type="journal"><name><surname>Wiersinga</surname><given-names>WM</given-names></name>. <article-title>Propranolol and thyroid hormone
metabolism</article-title>. <source>Thyroid</source>
<year>1991</year>;<volume>1</volume>:<fpage>273</fpage>&#x02013;<lpage>7</lpage>.<pub-id pub-id-type="pmid">1688102</pub-id></mixed-citation></ref><ref id="R109"><label>109.</label><mixed-citation publication-type="journal"><name><surname>Brunette</surname><given-names>DD</given-names></name>, <name><surname>Rothong</surname><given-names>C</given-names></name>. <article-title>Emergency department management of thyrotoxic crisis
with esmolol</article-title>. <source>Am J Emerg Med</source>
<year>1991</year>;<volume>9</volume>:<fpage>232</fpage>&#x02013;<lpage>4</lpage>.<pub-id pub-id-type="pmid">1673341</pub-id></mixed-citation></ref><ref id="R110"><label>110.</label><mixed-citation publication-type="journal"><name><surname>Knighton</surname><given-names>JD</given-names></name>, <name><surname>Crosse</surname><given-names>MM</given-names></name>. <article-title>Anaesthetic management of childhood thyrotoxicosis and
the use of esmolol</article-title>. <source>Anaesthesia</source>
<year>1997</year>;<volume>52</volume>:<fpage>67</fpage>&#x02013;<lpage>70</lpage>.<pub-id pub-id-type="pmid">9014549</pub-id></mixed-citation></ref><ref id="R111"><label>111.</label><mixed-citation publication-type="journal"><name><surname>Kidess</surname><given-names>AJ</given-names></name>, <name><surname>Caplan</surname><given-names>RH</given-names></name>, <name><surname>Reynertson</surname><given-names>MD</given-names></name>, <etal/>
<article-title>Recurrence of <sup>131</sup>I induced thyroid storm after
discontinuing glucocorticoid therapy</article-title>. <source>Wis Med
J</source>
<year>1991</year>;<volume>90</volume>:<fpage>463</fpage>&#x02013;<lpage>5</lpage>.<pub-id pub-id-type="pmid">1926884</pub-id></mixed-citation></ref><ref id="R112"><label>112.</label><mixed-citation publication-type="journal"><name><surname>Kawakami-Tani</surname><given-names>T</given-names></name>, <name><surname>Fukawa</surname><given-names>E</given-names></name>, <name><surname>Tanaka</surname><given-names>H</given-names></name>, <etal/>
<article-title>Effect of alpha hydroxyvitamin D3 on serum levels of thyroid
hormones in hyperthyroid patients with untreated Graves&#x02019;
disease</article-title>. <source>Metabolism</source>
<year>1997</year>;<volume>46</volume>:<fpage>1184</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="pmid">9322804</pub-id></mixed-citation></ref><ref id="R113"><label>113.</label><mixed-citation publication-type="journal"><name><surname>Benvenga</surname><given-names>S</given-names></name>, <name><surname>Lapa</surname><given-names>D</given-names></name>, <name><surname>Cannavo</surname><given-names>S</given-names></name>, <etal/>
<article-title>Successive thyroid storms treated with l-carnitine and low doses
of methimazole</article-title>. <source>Am J Med</source>
<year>2003</year>;<volume>115</volume>:<fpage>417</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="pmid">14553887</pub-id></mixed-citation></ref><ref id="R114"><label>114.</label><mixed-citation publication-type="journal"><name><surname>Benvenga</surname><given-names>S</given-names></name>, <name><surname>Ruggeri</surname><given-names>RM</given-names></name>, <name><surname>Russo</surname><given-names>A</given-names></name>, <etal/>
<article-title>Usefulness of l-carnitine, a naturally occurring peripheral
antagonist of thyroid hormone action, in iatrogenic hyperthyroidism: a
randomized, double-blind, placebo-controlled clinical trial</article-title>.
<source>J Clin Endocrinol Metab</source>
<year>2001</year>;<volume>86</volume>:<fpage>3579</fpage>&#x02013;<lpage>94</lpage>.<pub-id pub-id-type="pmid">11502782</pub-id></mixed-citation></ref><ref id="R115"><label>115.</label><mixed-citation publication-type="journal"><name><surname>Bennett</surname><given-names>MH</given-names></name>, <name><surname>Wainwright</surname><given-names>A</given-names></name>. <article-title>Acute thyroid crisis on induction of
anesthesia</article-title>. <source>Anaesthesia</source>
<year>1989</year>;<volume>44</volume>:<fpage>28</fpage>&#x02013;<lpage>30</lpage>.<pub-id pub-id-type="pmid">2929904</pub-id></mixed-citation></ref><ref id="R116"><label>116.</label><mixed-citation publication-type="journal"><name><surname>Dillman</surname><given-names>WH</given-names></name>. <article-title>Thyroid storm</article-title>. <source>Curr Ther
Endocrinol Metab</source>
<year>1997</year>;<volume>6</volume>:<fpage>81</fpage>&#x02013;<lpage>5</lpage>.<pub-id pub-id-type="pmid">9174709</pub-id></mixed-citation></ref><ref id="R117"><label>117.</label><mixed-citation publication-type="journal"><name><surname>Tietgens</surname><given-names>ST</given-names></name>, <name><surname>Leinung</surname><given-names>MC</given-names></name>. <article-title>Thyroid storm</article-title>. <source>Med Clin North
Am</source>
<year>1995</year>;<volume>79</volume>:<fpage>169</fpage>&#x02013;<lpage>84</lpage>.<pub-id pub-id-type="pmid">7808090</pub-id></mixed-citation></ref><ref id="R118"><label>118.</label><mixed-citation publication-type="journal"><name><surname>Leow</surname><given-names>MK</given-names></name>, <name><surname>Loh</surname><given-names>KC</given-names></name>. <article-title>Fatal thyroid crisis years after two thyroidectomies for
Graves&#x02019; disease: is thyroid tissue auto transplantation for
postthyroidectomy hypothyroidism worthwhile?</article-title>
<source>J Am Coll Surg</source>
<year>2002</year>;<volume>195</volume>:<fpage>434</fpage>&#x02013;<lpage>5</lpage>.<pub-id pub-id-type="pmid">12229955</pub-id></mixed-citation></ref></ref-list></back><floats-group><table-wrap id="T1" position="float" orientation="portrait"><label>Table 1</label><caption><p id="P56">Factors precipitating thyroid emergencies: myxedema coma and thyrotoxic
storm</p></caption><table frame="box" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th colspan="2" align="center" valign="bottom" style="border-bottom: solid 1px" rowspan="1">Precipitating Factors</th></tr><tr><th align="left" valign="bottom" rowspan="1" colspan="1">Myxedema Coma</th><th align="left" valign="bottom" rowspan="1" colspan="1">Thyrotoxic Storm</th></tr></thead><tbody><tr><td align="left" valign="bottom" rowspan="1" colspan="1">Drugs</td><td align="left" valign="bottom" rowspan="1" colspan="1">Drugs</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Withdrawal of L-thyroxine</td><td align="left" valign="bottom" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Withdrawal of antithyroid drug
treatment</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Anesthetics</td><td align="left" valign="bottom" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Radioactive iodine treatment</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Sedatives</td><td align="left" valign="bottom" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Thyroxine/triiodothyronine overdosage</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Tranquilizers</td><td align="left" valign="bottom" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Cytotoxic chemotherapy</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Narcotics</td><td align="left" valign="bottom" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Aspirin overdosage</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Amiodarone</td><td align="left" valign="bottom" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;lodinated contrast dyes</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Lithium carbonate</td><td align="left" valign="bottom" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Organophosphates</td></tr><tr><td colspan="2" align="left" valign="bottom" style="border-bottom: solid 1px" rowspan="1"/></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">Infections, sepsis</td><td align="left" valign="bottom" rowspan="1" colspan="1">Sepsis, infection</td></tr><tr><td colspan="2" align="left" valign="bottom" style="border-bottom: solid 1px" rowspan="1"/></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">Cerebrovascular accidents</td><td align="left" valign="bottom" rowspan="1" colspan="1">Seizure disorder</td></tr><tr><td colspan="2" align="left" valign="bottom" style="border-bottom: solid 1px" rowspan="1"/></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">Congestive heart failure</td><td align="left" valign="bottom" rowspan="1" colspan="1">Pulmonary thromboembolism</td></tr><tr><td colspan="2" align="left" valign="bottom" style="border-bottom: solid 1px" rowspan="1"/></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">Low temperatures</td><td align="left" valign="bottom" rowspan="1" colspan="1">Burn injury</td></tr><tr><td colspan="2" align="left" valign="bottom" style="border-bottom: solid 1px" rowspan="1"/></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">Trauma</td><td align="left" valign="bottom" rowspan="1" colspan="1">Surgery, trauma, vigorous palpation of
thyroid</td></tr><tr><td colspan="2" align="left" valign="bottom" style="border-bottom: solid 1px" rowspan="1"/></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">Metabolic disturbances</td><td align="left" valign="bottom" rowspan="1" colspan="1">Metabolic disturbances</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Acidosis</td><td align="left" valign="bottom" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Diabetic ketoacidosis</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Hypoglycemia</td><td align="left" valign="bottom" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Hypoglycemia</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Hyponatremia</td><td align="left" valign="bottom" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Hypercapnia</td><td align="left" valign="bottom" rowspan="1" colspan="1"/></tr><tr><td colspan="2" align="left" valign="bottom" style="border-bottom: solid 1px" rowspan="1"/></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">Other</td><td align="left" valign="bottom" rowspan="1" colspan="1">Other</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Gastrointestinal bleeding</td><td align="left" valign="bottom" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Parturition</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Ingestion of raw bok choy</td><td align="left" valign="bottom" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Emotional stress</td></tr></tbody></table></table-wrap><table-wrap id="T2" position="float" orientation="portrait"><label>Table 2</label><caption><p id="P57">Semiquantitative scale assessing the presence and severity of the most
common signs and symptoms</p></caption><table frame="box" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" valign="bottom" rowspan="1" colspan="1">Criteria</th><th align="left" valign="bottom" rowspan="1" colspan="1">Score</th></tr></thead><tbody><tr><td colspan="2" align="left" valign="bottom" style="border-bottom: solid 1px" rowspan="1">Thermoregulatory Dysfunction</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Temperature 99&#x000b0;&#x02212;99.9&#x000b0;F
(37.2&#x000b0;&#x02212;37.7&#x000b0;C)</td><td align="left" valign="bottom" rowspan="1" colspan="1">5</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Temperature
100&#x000b0;&#x02212;100.9&#x000b0;F
(37.8&#x000b0;&#x02212;38.2&#x000b0;C)</td><td align="left" valign="bottom" rowspan="1" colspan="1">10</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Temperature
101&#x000b0;&#x02212;101.9&#x000b0;F
(38.3&#x000b0;&#x02212;38.8&#x000b0;C)</td><td align="left" valign="bottom" rowspan="1" colspan="1">15</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Temperature
102&#x000b0;&#x02212;102.9&#x000b0;F
(38.9&#x000b0;&#x02212;39.3&#x000b0;C)</td><td align="left" valign="bottom" rowspan="1" colspan="1">20</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Temperature
103&#x000b0;&#x02212;103.9&#x000b0;F
(39.4&#x000b0;&#x02212;39.9&#x000b0;C)</td><td align="left" valign="bottom" rowspan="1" colspan="1">25</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Temperature &#x02265;104&#x000b0;F
(40&#x000b0;C) or higher</td><td align="left" valign="bottom" rowspan="1" colspan="1">30</td></tr><tr><td colspan="2" align="left" valign="bottom" style="border-bottom: solid 1px" rowspan="1"/></tr><tr><td colspan="2" align="left" valign="bottom" style="border-bottom: solid 1px" rowspan="1">Central Nervous System Effects</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Absent</td><td align="left" valign="bottom" rowspan="1" colspan="1">0</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Mild agitation</td><td align="left" valign="bottom" rowspan="1" colspan="1">10</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Delirium, psychosis, lethargy</td><td align="left" valign="bottom" rowspan="1" colspan="1">20</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Seizure or coma</td><td align="left" valign="bottom" rowspan="1" colspan="1">30</td></tr><tr><td colspan="2" align="left" valign="bottom" style="border-bottom: solid 1px" rowspan="1"/></tr><tr><td colspan="2" align="left" valign="bottom" style="border-bottom: solid 1px" rowspan="1">Gastrointestinal Dysfunction</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Absent</td><td align="left" valign="bottom" rowspan="1" colspan="1">0</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Diarrhea, nausea, vomiting, abdominal
pain</td><td align="left" valign="bottom" rowspan="1" colspan="1">10</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Unexplained jaundice</td><td align="left" valign="bottom" rowspan="1" colspan="1">20</td></tr><tr><td colspan="2" align="left" valign="bottom" style="border-bottom: solid 1px" rowspan="1"/></tr><tr><td colspan="2" align="left" valign="bottom" style="border-bottom: solid 1px" rowspan="1">Cardiovascular Dysfunction
(beats/min)</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;90&#x02013;109</td><td align="left" valign="bottom" rowspan="1" colspan="1">5</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;110&#x02013;119</td><td align="left" valign="bottom" rowspan="1" colspan="1">10</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;120&#x02013;129</td><td align="left" valign="bottom" rowspan="1" colspan="1">15</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;130&#x02013;139</td><td align="left" valign="bottom" rowspan="1" colspan="1">20</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x02265;140</td><td align="left" valign="bottom" rowspan="1" colspan="1">25</td></tr><tr><td colspan="2" align="left" valign="bottom" style="border-bottom: solid 1px" rowspan="1"/></tr><tr><td colspan="2" align="left" valign="bottom" style="border-bottom: solid 1px" rowspan="1">Congestive Heart Failure</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Absent</td><td align="left" valign="bottom" rowspan="1" colspan="1">0</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Mild (edema)</td><td align="left" valign="bottom" rowspan="1" colspan="1">5</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Moderate (bibasilar rales)</td><td align="left" valign="bottom" rowspan="1" colspan="1">10</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Severe (pulmonary edema)</td><td align="left" valign="bottom" rowspan="1" colspan="1">15</td></tr><tr><td colspan="2" align="left" valign="bottom" style="border-bottom: solid 1px" rowspan="1"/></tr><tr><td colspan="2" align="left" valign="bottom" style="border-bottom: solid 1px" rowspan="1">Atrial Fibrillation</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Absent</td><td align="left" valign="bottom" rowspan="1" colspan="1">0</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Present</td><td align="left" valign="bottom" rowspan="1" colspan="1">10</td></tr><tr><td colspan="2" align="left" valign="bottom" style="border-bottom: solid 1px" rowspan="1"/></tr><tr><td colspan="2" align="left" valign="bottom" style="border-bottom: solid 1px" rowspan="1">History of Precipitating Event</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Absent</td><td align="left" valign="bottom" rowspan="1" colspan="1">0</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Present</td><td align="left" valign="bottom" rowspan="1" colspan="1">10</td></tr></tbody></table><table-wrap-foot><fn id="TFN1"><p id="P58">Based on the total score, the likelihood of the diagnosis of
thyrotoxic storm is: unlikely, &#x0003c;25; impending, 25&#x02013;44; highly
likely, &#x0003e;45.</p></fn><fn id="TFN2"><p id="P59"><italic>Data from</italic> Burch HB, Wartofsky L. Life-threatening
thyrotoxicosis. Thyroid storm. Endocrinol Metab Clin North Am
1993;22:263&#x02013;77.</p></fn></table-wrap-foot></table-wrap></floats-group></article>